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For everything there is a season, 
and a time for every activity under heaven: 
A time to be born and a time to die, 
A time to plant and a time to uproot what was planted, 
A time to kill and a time to heal, 
A time to tear down and a time to build up, 
A time to weep and a time to laugh, 
A time to mourn and a time to dance, 
A time to cast away stones and a time to gather stones together, 
A time to embrace and a time to turn away, 
A time to search and a time to give up searching, 
A time to keep and a time to throw away, 
A time to tear and a time to mend, 
A time to be silent and a time to speak, 
A time to love and a time to hate, 
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Ageing related diseases become of ever more significance with the demographic shift 
currently prevalent in society. Dementia and movement disorders impact individuals 
and families alike, as the progressive decline in cognitive and physical abilities takes a 
toll on quality of life and an increasing strain on caretakers. Parkinson's disease (PD) is a 
neurodegenerative disorder that presents with movement-related symptoms due to 
degenerative processes in the midbrain, and that later can progress into changes in 
mood and behaviour, depression and dementia. PD primarily affects aged individuals, 
but genes of diverse cellular functions have been identified whose mutation can lead to 
an early—and even juvenile—onset of the disease. One major player in PD pathogenesis 
is α-Synuclein (ASYN), a small protein that has been identified as main component of PD-
related protein depositions. The cellular function of ASYN is still unknown, but mutation 
and overexpression leads to toxic gain of function and a link to PD pathogenesis is 
therefore indisputable. Studies have shown that ASYN pathology interferes with vesicle 
trafficking and assembly of the transport machinery. Genetic screens aimed at 
identifying modulators of ASYN toxicity identified gene clusters involved in vesicular 
trafficking. Likewise, studies in yeast could show that toxic levels of ASYN disrupt several 
steps of the protein transport machinery, most notably the ER-to-Golgi trafficking step 
that is crucial for correct post translational modification of several proteins. Further, 
ASYN pathology drastically interferes with the homeostasis of Rab GTPases, a family of 
proteins involved with vesicle trafficking, and it has been demonstrated that members 
of this family can alleviate ASYN toxicity. Here we show in a comprehensive screen of 
Rab GTPases with a mammalian cell model of ASYN inclusion formation that ASYN 
pathology leads to perturbation of Rab-related trafficking steps on a large scale. We 
identify two different endosomal pathways dysregulated upon appearance of 
intracellular protein depositions: the endosomal-lysosomal pathway which includes the 
early endosome, and the trans-Golgi network (TGN) recycling pathway. The small Rab 
GTPases Rab5A, Rab7 and Rab8A have fundamental impact on ASYN inclusion 
formation, secretion and toxicity. We demonstrate that Rab8A modulates ASYN 
inclusion formation and acts protective from ASYN mediated toxicity in our cellular 
model. Early endosomal Rab5A mislocalises upon ASYN inclusion formation, while 
lysosomal Rab7 increases ASYN inclusion formation, but fails to colocalize with them. 
We further use size exclusion chromatography (SEC) and enzyme linked immunosorbent 




ASYN particulate size and modulate secretion. Finally evaluating an animal model 
overexpressing human ASYN in a pan-neuronal manner we demonstrate upregulation of 
the lysosomal Rab7 and the protease Cathepsin D (CatD) in brain regions responsible for 
movement, motivation and memory formation. Our work both in mammalian cell 
culture as well as transgenic animals suggest that ASYN pathology impacts endosomal 
trafficking pathways, but also demonstrate the ability of proteins associated with the 
endosomal transport system to modulate ASYN associated toxicity. Thereby, anomalies 
in the trafficking machinery associated with endosomes caused by ASYN dysregulation 






Mit fortschreitendem Durchschnittsalter der Bevölkerung gewinnen altersbedingte 
Krankheiten immer mehr an Signifikanz. Demenz und Einschränkungen der 
Beweglichkeit wirken sich auf Individuen sowie auf Familien aus, da die progressive 
Abnahme kognitiver und physischer Fähigkeiten ihren Tribut von der Lebensqualität 
Betroffener sowie den Pflegenden fordert. Morbus Parkinson (PD) ist eine 
neurodegenerative Erkrankung, welche sich durch Symptome des Bewegungsapparates 
äußert, bedingt durch degenerative Prozesse im Mittelhirn, und welche mit 
Veränderungen des Gemütszustandes, Verhaltens sowie Depression und Demenz 
fortschreiten können. PD betrifft in der Regel ältere Personen, jedoch wurden Gene 
verschiedener zellulärer Funktionen identifiziert, deren Mutation zu einer frühen oder 
gar juvenilen Ausprägung der Krankheit führen kann. Ein Hauptakteur in PD ist α-
Synuclein (ASYN), ein kleines Protein welches in PD-typischen Proteinablagerungen 
gefunden wurde. Die zelluläre Funktion von ASYN ist immernoch unbekannt, Mutation 
oder Überexpression jedoch können zu einem hypermorphen Phänotyp führen und die 
Verbindung zu PD ist daher unumstritten. Studien haben gezeigt, dass ASYN mit 
Proteintransportwegen und der Aufstellung der Transportmaschinerie interferiert. 
Genetische Rasterstudien identifizierten Modulatoren von ASYN-Toxizität in Genclustern 
des Vesikeltransports. Ebenso konnten Studien in Hefe zeigen, dass Überexpression von 
ASYN diverse Transportwege stört, besonders zu beachten ist hier der ER-zu-Golgi 
Transportweg, welcher kritisch für Posttranslationale Modifikationen verschiedener 
Proteine ist. Des Weiteren greift ASYN-Pathologie störend in die Homöostase von Rab 
GTPasen ein, eine Proteinfamilie involviert in Vesikeltransport, manche deren Mitglieder 
ASYN-Toxizität reduzieren können. In dieser Studie zeigen wir in einer 
Rasteruntersuchung mit Rab GTPasen in einem Säugerzellmodell von ASYN-
Proteinanreichungen, dass die ASYN-Pathologe zu einer weitreichenden Störung von 
Rab GTPase assoziierten Transportwegen führt. Wir identifizieren zwei unterschiedliche 
endosomale Stoffwechselwege welche beim Auftreten von ASYN-Proteinablagerungen 
fehlreguliert werden: der endosomale-lysosomale-Proteintransportweg welcher das 
frühe Endosom beinhaltet, sowie den trans-Golgi Netzwerk (TGN) Transportweg. Die 
kleinen Rab GTPasen Rab5A, Rab7 und Rab8A haben fundamentale Auswirkungen auf 
die Formation von ASYN-Proteinansammlungen, Sekretion und Toxizität. Wir zeigen dass 
Rab8A in der Lage ist ASYN-Proteinansammlungen zu modulieren und agiert protektiv in 




Endosoms, fehllokalisiert mit Formation der Ablagerungen, während das lysosomale 
Rab7 die Anzahl der Ablagerungen erhöht, aber nicht ihnen kolokalisiert. Des Weiteren 
benutzen wir Größenexklusionschromatographie (SEC) und Enzyme Linked 
Immunosorbent Assay (ELISA) um zu zeigen, dass Rab5A und Rab7 in Abhängigkeit ihres 
Aktivitätszustandes die Partikelgröße von ASYN ändert und die Sekretion moduliert. Die 
abschließende Bewertung eines Tiermodells welches humanes ASYN pan-neuronal 
überexpremiert zeigte, dass lysosomales Rab7 und die Protease Cathepsin D (CatD) in 
Hirnregionen verantwortlich für Bewegung, Motivation und Gedächtnis herausreguliert 
sind. Unsere Arbeit sowohl in Säugerzellkultur sowie in transgenen Tieren deutet darauf 
hin, dass die ASYN-Pathologie Auswirkungen auf das endosomale Transportsystem hat, 
aber zeigt auch die Fähigkeit von Proteinen, welche mit diesem Transportsystem 
assoziiert sind, die Toxizität von ASYN zu modulieren. Daher schließen wir, dass 
Anomalien in der Transportmaschinerie von Endosomen, welche durch Fehlregulation 
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An aging society faces unique challenges. Some of these are to be found on the socio-
economic scale, but even more important are the ones in the health sector. Aging-
associated diseases range from cardiovascular conditions to cancer, hypertension and 
neurodegenerative diseases, to only name a few. Neurodegenerative conditions occur 
as several autonomous disorders, often characterized by subcellular protein deposits 
that can be located either inside or outside the cell. 
Examples of these disorders are amyloidoses and tauopathies, such as Alzheimer's 
disease (AD) which shows the accumulation of extracellular plaques and intracellular 
neurofibrillary tangles. Another example of neurodegenerative diseases is the family of 
synucleinopathies, which are characterized by the accumulation of intracellular 
inclusions primarily composed of the protein α-Synuclein (ASYN). The main types of 
synucleinopathies are PD, dementia with Lewy Bodies (DLB) and multiple system 
atrophy (MSA).  
 
1.1 Parkinson's Disease 
PD was first described by James Parkinson in 1817 (Parkinson, 1817). Currently, PD is 
estimated to affect up to 4% of the general population over 80 years of age (de Lau and 
Breteler, 2006). The major motor symptoms associated with PD are resting tremor, 
postural instability, rigidity and bradykinesia starting in the fine motor skills (Jankovic, 
2008). On a neuropsychiatric level, the symptoms include decreased cognitive speed and 
corresponding cognitive dysfunction, progressing dementia with accompanying 
alterations of mood and behavior have also been observed (Braak et al., 2002a, 2002b, 
2004). In other independent studies, non-classical symptoms were recently linked to PD; 
these include sleep disturbance, constipation, impotence and anosmia that often set in 
decades before the onset of the cardinal motor PD symptoms described above (Barone 
et al., 2009; Ferrer, 2011). PD is an idiopathic disorder and the causes are still unclear. 
Several factors that have been proposed to contribute to disease, including genetic, 
epigenetic and environmental circumstances, such as trauma and toxin exposure. While 
some toxins could be shown to cause symptoms concurrent with parkinsonism, with 
metals and neurotoxins being most prominent (Dauer and Przedborski, 2003), these 
1. Introduction  
2 
  
along with trauma and dementia pugilistica (Mendez, 1995; Erlanger et al., 1999), can be 
ruled out in most cases. 
Investigations of the molecular pathology of the disorder have revealed a progressive 
loss of dopaminergic neurons located in the substantia nigra (Davie, 2008). These 
neurons project into the striatum, the region of the midbrain that is responsible for 
motor control and coordination (Hodge and Butcher, 1980; Davie, 2008). Frederic Lewy 
described protein depositions in surviving neurons in post mortem brain tissue of PD 
sufferers (Rodrigues e Silva et al., 2010). These depositions are now called Lewy bodies 
(LBs) and are considered the major pathological hallmark of PD. They consist largely of 
ASYN, but also stain positive for ubiquitin (Spillantini et al., 1997; Goedert, 2001; Dauer 
and Przedborski, 2003; Engelender, 2008).  
At the beginning of the century, Heiko Braak proposed a staging of the disease according 
to LB pathology (Braak et al., 2004). The pattern of LB formation is ascending from the 
medulla towards the neocortex, in concordance to the progression of the symptoms. LB 
pathology confined to the brain stem either does not lead to symptoms or individuals 
thus affected only show non-classical symptoms. Only when LBs can be found in the 
substantia nigra, and about 50% of the dopaminergic neurons have died, the motor 
symptoms set in (Braak et al., 2002a, 2002b, 2004; Angot et al., 2010). When pathology 
progresses into the neocortex, neuropsychiatric symptoms are observed (Braak et al., 
2002a, 2002b, 2004). As neurons are postmitotic and terminally differentiated cells they 
are especially vulnerable to stress and injury and rely especially on an intact protein 
transport machinery to maintain their integrity and basic function. However, the reason 
for the special vulnerability of dopaminergic neurons is still not clear. Dopamine is a 
catecholamine and as such sensitive to reactive oxygen species, so one possibility lies in 
disruption of redox homeostasis (Dexter et al., 1987; Fariello, 1988; Sofic et al., 1988, 
1992; Spina and Cohen, 1989; Sian et al., 1994; Hashimoto et al., 1999; Nakaso et al., 
2013). This hypothesis is supported by the decreased glutathione and increased iron 
concentrations in the brains of affected individuals (Dexter et al., 1987; Sofic et al., 1988, 
1992; Spina and Cohen, 1989; Sian et al., 1994). Oxidation of dopamine caused the 
oxidative insults of these two conditions might lead to cytotoxicity. 
By now, several genes have been associated with PD (Table 1). Over the past decades, 
one of the strongest associations with the disease has turned out to be with ASYN 
(Figure 1), a small protein found both in the nucleus and at presynaptic termini 
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whose cellular function is still not fully understood. We will further try to shed some 
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Table 1: Genetics of PD 
Locus Gene Description Reference 
PARK 1/4 SNCA Presynaptic/nuclear 
protein 
(Polymeropoulos et al., 
1996) 
PARK2 Parkin Ubiquitin ligase (Kitada et al., 1998) 
PARK3 SPR(?)  (Gasser et al., 1998) 
PARK5 UCH-L1 Ubiquitin protease (Liu et al., 2002) 
PARK6 PINK1 Mitochondrial 
protein kinase 
(Hatano et al., 2004) 
PARK7 DJ-1 Multifunctional 
protein 
(Bonifati et al., 2003) 
PARK8 LRRK2 Leucine-rich repeat 
kinase 
(Gasser, 2009) 
PARK9 ATP13A2 Lysosomal ATPase (Ramirez et al., 2006) 
PARK10 (?)  (Li et al., 2002) 
PARK11 GIGYF2  (Lautier et al., 2008) 
PARK12 (?)  (Pankratz et al., 2002) 
PARK13 Omi/HTRA2 Serine Protease (Strauss et al., 2005) 
PARK14 PLA2G6 Phospholipase (Paisan-Ruiz et al., 2009) 
PARK15 FBXO7 F-box protein (Shojaee et al., 2008) 
PARK16 (?)  (Satake et al., 2009) 
PARK17 VPS35 Retromer Complex (Wider et al., 2008) 
PARK18 EIF4G1 Translation 
Initiation Factor 
(Chartier-Harlin et al., 2011) 
PARK19 DNAJC6 DNAJ/HSP40 
homolog 
(Edvardson et al., 2012) 






1.2 ASYN, a central player in PD 
ASYN is the main component of LBs (Spillantini et al., 1997) and it has long been defined 
as a natively unfolded protein able to assume α-helical secondary structure (Chandra et 
al., 2003) (Figure 1B), form homodimers, and fibrillize into detergent insoluble 
aggregates (Conway et al., 1998). Several studies also discussed a potential tetrameric 
structure under physiological conditions (Bartels et al., 2011; Wang et al., 2011). The α-
helically folded form of the protein is the one thought to preferentially interact with 
membranes. In any case, the existence of tetrameric ASYN remains controversial (Binolfi 
et al., 2012; Fauvet et al., 2012a, 2012b). This can also be attributed to a follow up study 
that found differently modified, native and recombinant ASYN to have similar 
electrophoretic mobility, mass, and circular dichroism spectra concurrent with results 
for monomers (Fauvet et al., 2012b). Due to the exhaustive nature of the study 
employing transgenic mice expressing human ASYN, rat brains expressing human ASYN 
after AAV infection, human erythrocytes and brain post mortem samples as well as 
recombinant protein (Fauvet et al., 2012b), it seems more likely that ASYN exists 
predominantly as a natively unfolded monomer.  
While LBs are the pathological hallmark of PD, the deposits are found in surviving 
neurons, which might present an effort of the cells to protect themselves by 
sequestering exogenous protein into LBs. Due to this hypothesis, it might be that lower 
molecular weight ASYN oligomers constitute the toxic species (Winner et al., 2011). 
Lesions from autopsied PD brains show a marked increase in S129 hyperphosphorylated 
ASYN (Fujiwara et al., 2002). Still, the exact determinants that lead to ASYN misfolding 
and fibrillization remain unclear. Nonetheless, multiple factors might be involved in this 
process. 
Given that ASYN interacts with membranes, it is likely that fibril formation might 
interfere with normal membrane dynamics (Zhu et al., 2003; Fortin et al., 2004; Jo et al., 
2004), and that the physiological function of ASYN might be related to membrane 
integrity or protein trafficking pathways. Several studies support the interaction of ASYN 
with the trafficking machinery: ASYN regulates the size of the presynaptic vesicle pool in 
primary hippocampal neurons (Murphy et al., 2000), might have a chaperone activity to 
other presynaptic membrane proteins (Chandra et al., 2005) and plays a role in SNARE 
complex assembly (Burré et al., 2010; Thayanidhi et al., 2010), can interact with Rab 
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GTPases (Sung et al., 2001; Dalfó et al., 2004a; Cooper et al., 2006; Gitler et al., 2008; 
Soper et al., 2008, 2011; Liu et al., 2009; Sancenon et al., 2012; Rendón et al., 2013; 
Breda et al., 2014; Chutna et al., 2014; Yin et al., 2014), and is involved in vesicle 
recycling (Ben Gedalya et al., 2009; Nemani et al., 2010; Scott and Roy, 2012). Additional 
evidence for the association of ASYN with membranes can be derived from biochemical 
and biophysical studies: acetylation at the N-terminus of ASYN leads to an increased 
membrane binding affinity (Bartels et al., 2011; Fauvet et al., 2012a; Kang et al., 2012; 
Maltsev et al., 2012), while nitration of C-terminally-located tyrosines leads to a partial 
abolishment of membrane binding (Sevcsik et al., 2011). 
Missense mutations and multiplications of the gene encoding for ASYN cause autosomal 
dominant forms of PD (Golbe et al., 1990; Polymeropoulos et al., 1996, 1997; 
Polymeropoulos, 1997; Krüger et al., 1998; Singleton et al., 2003; Chartier-Harlin et al., 
2004; Zarranz et al., 2004; Kiely et al., 2013; Proukakis et al., 2013; Pasanen et al., 2014) 
(Figure 1A). So far, six familial missense mutations of ASYN have been found: A30P 
(Krüger et al., 1998), E46K (Zarranz et al., 2004), H50Q (Proukakis et al., 2013), G51Q 
(Kiely et al., 2013) A53E (Pasanen et al., 2014) and A53T (Golbe et al., 1990; 
Polymeropoulos et al., 1996; Polymeropoulos, 1997). Additionally, duplication (Chartier-
Harlin et al., 2004) and triplication (Singleton et al., 2003) of the SNCA locus also lead to 
disease onset. All of these studies provide a strong link between ASYN and PD. 
Exogenous amounts of wild type (wt) ASYN and disease-associated mutations caused by 
overexpression has been shown to induce toxicity in a variety of cellular and animal 
models, such as yeast, worms, flies, or mice (Masliah et al., 2000; van der Putten et al., 
2000; Giasson et al., 2002; Outeiro and Lindquist, 2003; Singleton et al., 2003; Chartier-





Figure 1: ASYN mutations and secondary structure. (A) The N-terminus with KTKEGV repeats (green) is able 
to assume α-helical structure (Jao et al., 2004) upon binding to membranes as displayed in (B). The non-
amyloid component (NAC) domain is displayed in red. The C-terminus is highly unstable and modifications 
can aid aggregate formation. Amino acid positions A30, E46, H50, G51 and A53 have been associated with 
familial PD. (B) Structure of membrane bound ASYN colored in secondary structure succession by Swiss Pdb-
Viewer (Guex and Peitsch, 1997). Sites of familial mutations are marked in purple. PDB entry 1XQ8 (Ulmer et 
al., 2005). 
Overexpression of human wt and mutant ASYN in mice leads to lesions in the spinal 
cord, brainstem, hippocampus and neocortex as well as motor phenotypes (Masliah et 
al., 2000; van der Putten et al., 2000; Giasson et al., 2002; Rockenstein et al., 2002; 
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Fleming et al., 2004). Interestingly, expression of the ASYN transgene in a cysteine string 
protein α (CSPα) mouse knockout model is able to rescue neurodegeneration caused by 
the null mutation (Chandra et al., 2005). ASYN also seems to play a role in SNARE 
complex assembly (Burré et al., 2010; Thayanidhi et al., 2010), which is further validated 
by the fact that ASYN co-immunoprecipitates with SNAP-25, and directly interacts with 
VAMP2 in vitro (Burré et al., 2010).  
 
Further evidence for a role of ASYN in the cellular transport machinery stems from 
studies in yeast. While yeast does not have a native homologue for ASYN, nevertheless, 
it has proven to be an invaluable model organism. In genome wide screens in yeast, 
multiple genes were identified to enhance or suppress ASYN toxicity (Outeiro and 
Lindquist, 2003; Willingham et al., 2003; van Ham et al., 2008). It is striking that many of 
the thus identified gene clusters are related to either lipid metabolism or vesicular 
transport. A high percentage of these genes have human orthologs. It was first proven in 
yeast that Ypt1, the yeast homologue of mammalian Rab1, can alleviate a ER-to-Golgi 
vesicle trafficking block caused by ASYN (Cooper et al., 2006; Gitler et al., 2008). The 
results of these studies could be repeated in other model systems (Cooper et al., 2006).  
In an RNAi screen in Caenorhabditis elegans, several genes associated with trafficking 
were identified to act neuroprotective on ASYN-induced toxicity (Hamamichi et al., 
2008; Kuwahara et al., 2008; van Ham et al., 2008). 
 
1.3 ASYN and synaptic vesicles 
ASYN is present at presynaptic termini (Maroteaux et al., 1988). This, along with its 
membrane binding capability and association with synaptic vesicles suggests a role in 
endo- or exocytosis, which are essential processes for the function and survival of 
neuronal cells. Under physiological conditions synaptic vesicles dock to and fuse with 
the plasma membrane, which releases neurotransmitters into the synaptic cleft. They 
are then replenished via recycling, as well as from the distal vesicle pool. This vesicle 
reserve pool is diminished upon ASYN knockdown in primary hippocampal neurons, and 
this suggests that ASYN might be involved in the regulation of vesicle pools (Murphy et 
al., 2000; Cabin et al., 2002).  
1. Introduction 
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Electrophysiological studies support this observation, as they show no alteration in basal 
transmission, but depletion of the docked vesicles and distal reserve pool upon 
prolonged stimulation (Cabin et al., 2002). Supporting this is the observation that aged 
ASYN null mice show reduced dopamine content in the striatum, while no such 
progressive loss could be observed in the substantia nigra pars compacta (Al-Wandi et 
al., 2010). The normal function of ASYN therefore might be involved in the dopamine 
cycle, however this does not explain the toxic gain of function observed upon increased 
gene dose or mutation. If ASYN should be a deciding factor in exocytosis, oxidative insult 
might lead to a diminishment of membrane binding of ASYN and, therefore, to 
dysfunction in neurotransmitter release (Sevcsik et al., 2011). Increased expression of 
ASYN in chromaffin PC12 cells concurs with an inhibition of dopamine release, but it 
increases the number of vesicles docked to the plasma membrane (Larsen et al., 2006). 
These results are somewhat controversial, but might be cell line specific. A reduction in 
released vesicles was also observed in mouse primary hippocampal cultures (Nemani et 
al., 2010). While subsequent in vivo studies with wt and A30P ASYN revealed no 
alteration in amount of docked vesicles in primary chromaffin cells, a significant 
reduction of neurotransmitter release was shown (Larsen et al., 2006), as well as an 
inhibition of synaptic transmission in acute hippocampal slices, electrochemical caudate 
putamen measurements and primary midbrain dopaminergic neurons (Nemani et al., 
2010; Scott et al., 2010; Lundblad et al., 2012; Scott and Roy, 2012). Due to these 
findings, it is possible that ASYN pathology is related to secretion and vesicle recycling. 
Vesicle clustering and reclustering is non-uniform in synapses of ASYN overexpressing 
animals and this goes in hand with unusual, non-uniform vesicle sizes (Nemani et al., 
2010; Scott et al., 2010). Overall changes to the ultrastructure of the presynapse seem 
plausible due to these changes in the vesicle pools and synaptic transmission. Whether 
this directly related to abnormal ASYN interactions with synaptic vesicles or components 
of the underlying trafficking machinery remains unknown. 
 
1.4 Rab GTPases 
The family of Rab GTPases is a class of peripheral membrane proteins mainly involved in 
trafficking. They are molecular switches and present key regulatory factors in a 
multitude of trafficking and vesicle movement steps between organelles.  
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More than 60 members of the Rab family have so far been identified in mammals, many 
of them with up to four isoforms, with 11 homologues in yeast. Rabs are highly 
conserved (Pereira-Leal and Seabra, 2001; Chan et al., 2011; Diekmann et al., 2011) with 
a GTPase fold that can be found in all members of the Ras superfamily identified so far 
and which is responsible for the activation state of the protein. The C-terminus is highly 
variable and one of the defining structural characteristics between different members of 
the Rab GTPase family (Lee et al., 2009).  
Rab GTPases are present in a GTP-bound—active—and GDP-bound—inactive—
conformation (Figure 2A) and cycle between the target membrane and the cytosol. They 
can be considered molecular switches, as they cover a significant role in the formation, 
budding, fusion, molecular transport as well as tethering of a vesicle. GDP is exchanged 
for GTP by guanosine exchange factors (GEFs) and GTP is cleaved by interaction of Rabs 
with a GTPase activating protein (GAP) (Fischer von Mollard et al., 1994a; Lee et al., 
2009) (Figure 2A). Rabs can themselves interact with other proteins, which are then 
called effectors and carry out diverse functions, depending on their localization and 
specific function in the membrane trafficking pathway (Pfeffer, 2001; Lee et al., 2009; 
Hutagalung and Novick, 2011) (Figure 2B). Thus, the specific Rab is one factor that 
contributes to membrane and thereby organelle identity (Chavrier et al., 1990b; Pfeffer, 
2001) (Figure 2B, Figure 3, Figure 4A). Rab GTPases mutants have been described that 
are impaired in intrinsic GTP hydrolysis, termed constitutive active (Bucci et al., 1992, 
2000; Vitelli et al., 1997), or that have a greatly reduced affinity to GTP, termed 
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Figure 2: Rab GTPases are molecular switches that act to coordinate membrane trafficking. (A) Rabs are 
present in active GTP-bound and an inactive GDP-bound state. Conversion from the inactive to the active 
state is facilitated by GEFs and causes a conformational change that activates the protein, the active state is 
recognized by effector proteins. These GAPs stimulate the inherent GTPase activity and an inorganic 
phosphate molecule is released, rendering the Rab inactive. (B) Rabs functions in vesicle trafficking. Distinct 
membrane trafficking steps that can be controlled by a Rab GTPase and its effectors (indicated in orange). 
(a) An active GTP-bound Rab can activate a sorting adaptor to sort a receptor into a budding vesicle. (b) 
Through recruitment of phosphoinositide (PI) kinases or phosphatases, the PI composition of a transport 
vesicle might be altered (the conversion of PI-x into PI-y) and thereby cause uncoating through the 
dissociation of PI-binding coat proteins. (c) Rab GTPases can mediate vesicle transport along actin filaments 
or microtubules (collectively referred to as cytoskeletal tracts) by recruiting motor adaptors or by binding 
directly to motors (not shown). (d) Rab GTPases can mediate vesicle tethering by recruiting rod-shaped 
tethering factors that interact with molecules in the acceptor membrane. Such factors might interact with 
SNAREs and their regulators to activate SNARE complex formation, which results in membrane fusion. (e) 
Following membrane fusion and exocytosis, the Rab GTPase is converted to its inactive GDP-bound form 
through hydrolysis of GTP, which is stimulated by a GAP. Targeting of the Rab-GDP dissociation inhibitor 
(GDI) complex back to the donor membrane is mediated by interaction with a membrane-bound GDI 
displacement factor (GDF). Conversion of the GDP-bound Rab into the GTP-bound form is catalysed by a 
GEF. (Figure 2B and accompanying description originally by Harald Stenmark (Stenmark, 2009).) 
 
The exchange of one Rab replacing another on a membrane, e.g. from early endosome 
to late endosome, is called Rab conversion (Rink et al., 2005; Poteryaev et al., 2010). In 
this process, the loss of one Rab is coordinated with the acquisition of another, each 
binding to its own domain on the target membrane (Sönnichsen et al., 2000; Rink et al., 
2005). On the molecular level, this conversion is facilitated by Rab effector molecules 
(Rink et al., 2005; Poteryaev et al., 2010). 
Rabs are integral membrane proteins and due to their previously mentioned 
involvement in ASYN pathology a prime target for further investigation. For this study, 
we selected three Rab GTPases to investigate further in the context of ASYN pathology, 
namely Rab5A, Rab7 and Rab8A which we will highlight further.  
 
1.4.1 Rab5A 
Rab5A is a regulator of clathrin-mediated endocytosis as well as early endosome 
biogenesis and fusion (Chavrier et al., 1990a; Bucci et al., 1992; Fischer von Mollard et 
al., 1994b; Stenmark et al., 1994; Zeigerer et al., 2012) (Figure 3). Overexpression of wt 
1. Introduction 
13 
and constitutively active Rab5 leads to accelerated endocytosis and abnormally large 
endosomes (Bucci et al., 1992), while dominant negative Rab5 can inhibit endocytosis 
and prevent the fusion of early endosomal membranes (Stenmark et al., 1994). Rab5 is 
involved in endocytic sorting in axonal trafficking (Deinhardt et al., 2006) and has 
recently been found to be necessary for the formation of the autophagosome (Ao et al., 
2014). No disease associated mutations have been identified as of yet, which highlights 
its general importance in trafficking events. On the other hand, Rab5 is able to aid in 
facilitating pathogenic entrance into cells (Gimenez et al., 2015). Rab5 interacts with 
mutant ASYN A30P in vivo (Dalfó et al., 2004b) and is upregulated in human cases of 
mild cognitive impairment and AD (Ginsberg et al., 2010, 2011). 
 
1.4.2 Rab7 
Rab7 has been dubbed "a key to lysosomal biogenesis" (Bucci et al., 2000) and is an 
important regulator of the endo-lysosomal system as well as autophagosome formation 
(Chavrier et al., 1990a; Mukhopadhyay, 1997; Bucci et al., 2000; Gutierrez et al., 2004; 
Deinhardt et al., 2006; Silverman et al., 2011; Ng et al., 2012; Aloisi and Bucci, 2013; Ao 
et al., 2014). The late endosome and lysosome only achieve their identity after Rab 
conversion where Rab5 is exchanged for Rab7 at their discreet domains on the 
endosomal membrane (Rink et al., 2005) (Figure 3). Overabundance of wt or expression 
of constitutively active Rab7 lead to enlarged late endosomes and lysosomes, localized 
mainly in the perinuclear region, while expression of dominant negative Rab7 leads to 
reduced acidity and dispersal of the lysosome (Bucci et al., 2000). Several studies have 
associated other mutations of Rab7 with the inherited motor and neurological disorder 
Charcot-Marie-Tooth disease type 2B (Spinosa et al., 2008; McCray et al., 2010; Bucci 
and De Luca, 2012). Besides these, one study found Rab7 to be upregulated in human 
cases of mild cognitive impairment and AD (Ginsberg et al., 2010, 2011). Interestingly, 
Rab7 interacts with leucine-rich-repeat-kinase 2 (LRRK2), another gene associated with 
familial forms of PD (Gasser, 2009; Dodson et al., 2012; Gómez-Suaga et al., 2014). In D. 
melanogaster, mutant LRRK2 homologue interferes with Rab7 mediated lysosomal 
positioning (Dodson et al., 2012). In HeLa and HEK293 cells, expression of mutant LRRK2 
leads to impaired receptor degradation, possibly by downregulating Rab7 activity and 
the associated pathway (Gómez-Suaga et al., 2014). Expression of constitutive active 
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Rab7 rescues this delay and restores the late endocytic trafficking pathway (Gómez-
Suaga et al., 2014). 
 
Both Rab5 and Rab7 are key factors ensuring normal progression through the endocytic 
pathway (Figure 3).  
 
Figure 3: Model, describing endocytic organelles as a mosaic of membrane domains. Each Rab domain 
fulfills a different cellular function. Cargo enters the cells via the Rab5-mediated endocytic pathway and first 
enters Rab5 positive structures. Rapid sorting into Rab4 and Rab11 positive recycling endosomes occurs via 
sorting mechanisms. In the endocytic degradation pathway cargo is shifted from sorting endosomes into 
late endosomes positive for Rab7 and Rab9. From here material is either recycled via the trans-Golgi 
network or degraded in the lysosome. (Modified from Marino Zerial, Max-Planck-Institute of Molecular Cell 





Rab8A is located in the TGN where it regulates apical transport events that pass through 
recycling endosomes (Hattula et al., 2006; Henry and Sheff, 2008), placing it in the 
secretory pathway. Compartments positive for Rab8A can be tubular in shape (Hattula 
et al., 2006), and constant activation leads to disturbances in protein sorting events 
(Henry and Sheff, 2008), while expression of the dominant negative version of the 
protein has an effect of cell shape and adhesion (Hattula et al., 2006). As Rab8A is also 
involved in ciliogenesis, disturbances in Rab8A homeostasis are implicated in microvillus 
inclusion disease and Bardet-Biedl syndrome (Nachury et al., 2007; Erickson et al., 2008). 
 
1.5 ASYN and Rab GTPases 
Several studies have linked Rab GTPases to PD and ASYN pathology thus far. In brain 
tissue from DLB and MSA patients as well as in transgenic mouse lines, co-
immunoprecipitation studies showed interaction between ASYN and Rab3A, Rab5 and 
Rab8 (Dalfó et al., 2004a, 2004b; Dalfó and Ferrer, 2005) (Figure 4B). Rab3A is the 
neuronal isoform of Rab3 and present in almost all synapses in the brain. Knockout 
mutants are viable and fertile due to redundancy (Fischer von Mollard et al., 1991; 
Geppert et al., 1994). One of its effectors is rabphilin (Geppert et al., 1994), and the 
same study also showed an interaction with ASYN (Dalfó et al., 2004a). Interaction of 
high molecular weight species of ASYN and Rab3A, Rab5, Rab8 and rabphilin could only 
be found in the detergent insoluble fraction of patients' brains, while slight interaction 
with the monomer was observed in the soluble fraction of control brains (Dalfó et al., 
2004b; Dalfó and Ferrer, 2005). Rab3 and Rab8 are involved in exocytosis, while Rab5 is 
in the endocytic pathway and due to the aforementioned results and similar findings in 
A30P transgenic mice, it has been hypothesized that these two crucial cellular functions 
are dysregulated in synucleinopathies (Dalfó et al., 2004b) (Figure 4B). Overexpression 
of inactive Rab5a can reduce cell death induced by exogenous addition of ASYN (Sung et 
al., 2001; Potokar et al., 2012). Further, in an ASYN transgenic mouse model, as well as 
brains from DLB and AD patients, Rab5-positive endosomal structures are enlarged and 
Rab5 is dysregulated (Sancenon et al., 2012) (Figure 4B). In a cell model with ASYN A30P 
overexpression, co-expression of Rab1A, Rab7 and Rab8A yielded a two-fold higher 
secretion of ASYN into the medium, while Rab7 and Rab8A also decreased toxicity 
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(Ejlerskov et al., 2013). In the same study, modulation of Rab27A activity could show a 
modulation of ASYN secretion and mortality. While extracellular ASYN is endocytosed in 
a Rab regulated manner, recycling and exocytosis also involve Rab GTPases. Rab11a, 
which characterizes recycling endosomes, interacts with endocytosed ASYN in cellular 
models, where it modulates secretion, ASYN aggregation and toxicity (Liu et al., 2009; 
Chutna et al., 2014). Heat shock protein 90 (HSP90) interacts with Rab11a, but is also 
involved in the recycling pathway of endocytosed ASYN (Liu et al., 2009). Whether these 
results could be exploited for clearance of intracellular ASYN or ASYN aggregates 
remains unknown, although ASYN and Rab11A have been shown to interact in vivo in 
mice (Chutna et al., 2014) and could alleviate ASYN mediated toxicity in Drosophila 
melanogaster model (Breda et al., 2014), possibly by restoring homeostasis to the 






Figure 4: Hypothetical model for vesicular trafficking pathways with selected regulatory factors associated 
with ASYN pathology. (A) Under normal homeostatic conditions cargo vesicles bud off the ER and are 
shuttled to the Golgi apparatus with the help of Rab1. After processing in the Golgi, vesicles are processed 
by the TGN and either enter the secretory pathway where they are associated with Rab8 and Rab3 or are 
transported to one endosomal compartments. Rab5 mediated endocytosis directs vesicles either to the 
Golgi apparatus or to an endosome. Anterograde as well as retrograde traffic between the endosome and 
the Golgi is facilitated by Rab6. As the endosome matures, Rab5 is replaced by Rab7 at its membrane, 
signifying a slow acidification and eventual lysosomal function. Rab11 at recycling endosomes facilitates a 
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steady exchange with the extracellular space. Fusion of vesicles with the plasma membrane for exocytosis is 
facilitated by zippering of SNARE proteins; t-SNAREs, here SNAP25, and v-SNAREs, here VAMP2, zipper 
together to enable fusion of the two membranes. (B) Hypothetical model of how several regulatory factors 
could be affected by ASYN toxicity. Several discrete trafficking steps are associated with ASYN pathology. 
ASYN oligomers associate with the ER membrane, causing stress and leading to cellular toxicity. Aggregation 
of ASYN leads to a trafficking block between the ER and the Golgi apparatus, which can be alleviated by 
overexpression of Rab1. The TGN and secretory pathway are inhibited, and vesicular clustering can be 
observed. Rab5 mediated endocytosis is inhibited and the formation of SNARE complexes is disturbed. 
Interrupted arrows signify disturbances in vesicular trafficking pathways. ASYN is not displayed due to 
unknown nature of aggregation state, the condition is instead symbolized by shading of the cytoplasm. 
(Modified from (Eisbach and Outeiro, 2013).) 
 
Interactions between ASYN and the family of Rab GTPases have been most extensively 
studied in yeast, where several vesicle trafficking steps were identified to be affected by 
ASYN overexpression (Figure 4). An ASYN mediated ER to Golgi trafficking (Cooper et al., 
2006) which could be repeated in cell free systems, where transport is reduced by 50% 
(Gitler et al., 2008). Overexpression of the Rab1 homologue Ypt1 alleviates the 
trafficking block and rescues cytotoxicity. Rab1 could afterwards reduce toxicity in flies, 
nematodes primary neuronal cultures (Cooper et al., 2006). In yeast, ASYN 
overexpression leads to protein foci attached to the plasma membrane (Gitler et al., 
2008; Soper et al., 2008), but strong overexpression of Ypt1 was able to reduce the size 
of the foci and ASYN toxicity (Gitler et al., 2008). The Rab homologues Ypt31, Sec4, Ypt6, 
Vps21, Ypt52 and Ypt7 all colocalize with ASYN accumulations in yeast, but none of 
these genes suppresses ASYN toxicity. Human Rab1, Rab3a and Rab8a were able to 
significantly rescue toxicity (Gitler et al., 2008) in C. elegans. It is worth highlighting 
these three Rabs are associated with Golgi or TGN trafficking respectively. Subsequently, 
Yptp6p, Yptp7p, Ypt10p, Ypt31p, Ypt32p, Ypt51p and Ypt53p were found to colocalize 
with ASYN in an with only Ypt10p partially localizing to its normal target membrane 
(Soper et al., 2011). In knockout mutants of Rab homologues that express ASYN, 
inactivation of Ypt6p led to an increase in vesicle clustering. In yeast expressing ASYN 
and Ypt6p reduced vesicle clustering was observed this yeast homologue of Rab6 to be a 
regulator of ASYN toxicity. In the same study, deletion of Ypt7p, yeast homologue of 
Rab7, and Ypt51p, homologue of Rab5, also led to increases in vesicle clustering, but to 
a lesser degree than Ypt6p (Soper et al., 2011). These proteins are all involved neuronal 
endocytosis, the TGN and the endosomal pathway (Fischer von Mollard et al., 1994b; 
Sung et al., 2001; Rink et al., 2005; Utskarpen et al., 2006; Potokar et al., 2012), which 
1. Introduction 
19 
suggests that ASYN pathology could interfere with Golgi or endosome trafficking 
pathways. Further evidence of this has been found in one of our own studies, in which 
we could prove ASYN interaction with Rab8A in vitro as well as in vivo and found Rab8A 
interact with the C-terminus of ASYN and modulates inclusion formation and toxicity 
both in a cellular and a D. melanogaster model (Yin et al., 2014).  
In ASYN transgenic C. elegans, pan-neuronal knockdown of Rab7 caused severe motor 
and growth abnormalities (Kuwahara et al., 2008). In primary neurons, axonal transport 
of Rab7 positive compartments is impaired by immobilized ASYN inclusions (Volpicelli-
Daley et al., 2014). 
Another Rab-related ASYN interactor is prenylated Rab acceptor protein 1 (PRA1) (Lee et 
al., 2011). PRA1 binds to Rab1, Rab3a, Rab5 and Rab6, placing it into the Golgi and 
endosomal trafficking pathways (Figueroa et al., 2001). In cells co-expressing PRA1 and 
ASYN, vesicles were translocated towards the cell periphery (Lee et al., 2011).These 
studies suggest that overexpression of ASYN seems to interfere with a variety of 
trafficking steps; from transport vesicles of newly translated proteins between ER and 
Golgi to endo- and exocytosis and retrograde protein transport. Interestingly, numerous 
members of the Rab GTPase family appear to be dysregulated by ASYN, whether this is 
causative to the trafficking defects or a consequence of them remains unknown, as well 
as how exactly ASYN interferes with vesicular transport events.  
 
1.6 Spreading of ASYN pathology between cells 
PD is a progressive disease and when we consider the different stages (Braak et al., 
2004) that suggest LB pathology to be ascending from the medulla into the neocortex 
concurrent with physical and cognitive symptoms (Braak et al., 2002a, 2002b, 2004), we 
have to take the presence of an infectious agent into account. In an effort to alleviate PD 
motor symptoms, patients received embryonic nigral transplants into their own 
midbrains (Freed et al., 2001). In post mortem investigations, researchers discovered the 
presence of LB-like pathology in these transplants (Kordower et al., 2008a, 2008b; Li et 
al., 2008). Studies with stem cells transplants in mice have yielded comparable results 
(Desplats et al., 2009). This is surprising because PD is a disease that mostly occurs 
sporadically in aged individuals and, therefore, LBs—the pathological hallmark of the 
disease—should not be present in transplanted embryonic tissue. While 
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microenvironmental factors in diseased brains could be at fault and cause inclusion 
formation, the connection to Braak staging is obvious. The high concentration of ASYN in 
LBs make it an attractive candidate and indeed, several studies have shown that ASYN 
can be secreted (El-Agnaf et al., 2003; Liu et al., 2009; Jang et al., 2010) and that it can 
enter cells from the extracellular space via Rab mediated endocytosis (Sung et al., 2001) 
and even a clathrin-dependent pathway (Liu et al., 2007; Ben Gedalya et al., 2009). The 
question remains of how such a transmission would be possible. One attractive 
explanation is that of a prion-like mechanism of transmission, especially since studies 
have proposed a similar mechanism for amyloid-β and tau in AD (Angot et al., 2010; 
Steiner et al., 2011). While secretion and uptake of ASYN probably present natural 
cellular mechanisms, ASYN inclusion formation would likely require a seed. In spread of 
prion disease, a single misfolded PrP molecule is sufficient to act as a nucleus leading to 
further events of misfolding (Laurén et al., 2009). Accordingly, one pathologic event in 
ASYN folding or oligomerization would be enough to infect the rest of the cell and lead 
to similar events in neighboring cells, if secretion and uptake occur (Angot et al., 2010; 
Steiner et al., 2011). This theory was already successfully tested using neuroblastoma 
cells (Hansen et al., 2011). In another study, inoculation of mice brains with brain 
extracts from sick mice led to an earlier onset of symptoms and immuoreactivity to 
disease-associated ASYN throughout the brain (Bétemps et al., 2014). Another in vivo 
study where the authors injected recombinant ASYN fibrils into the substantia nigra of 
wt mice reported slow neurodegeneration due to neuronal dysfunction due to ASYN 
spreading in a prion-like manner (Masuda-Suzukake et al., 2013). Progressive loss of 
dopaminergic neurons with motor deficits could be shown after seeding of recombinant 
ASYN fibrils into the striatum, indicating cell-to-cell spread of pathogenic ASYN in 
anatomically connected brain regions (Luk et al., 2012). 
Interestingly, oligomers in the instance of ASYN present the smallest unit with the ability 
to seed aggregation, as it has been shown that fibrils from recombinant ASYN are also 
able to seed aggregation in primary neurons (Volpicelli-Daley et al., 2011, 2014) and 
then be transported to the soma in an axon dependent manner (Volpicelli-Daley et al., 
2011, 2014; Freundt et al., 2012). How large oligomer fibrils and aggregates would be 
able to be secreted is still under debate, however we should consider the possibility that 
these might originate from dead cells releasing their content into the extracellular space 
(Steiner et al., 2011). It has been shown that ASYN can be released into the extracellular 
space via exosomes (Emmanouilidou et al., 2010; Danzer et al., 2012), small 
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membranous vesicles derived from late endosomes (Bucci et al., 2000). Both monomeric 
and oligomeric ASYN is packaged into exosomes and secreted (Emmanouilidou et al., 
2010; Danzer et al., 2012), and can be toxic for several cell types when exosome 
containing medium is added to them (Emmanouilidou et al., 2010; Danzer et al., 2012). 
Ultimately, cell-to-cell spread of ASYN would explain correlation between symptom 
severity and ascending pathology as described by Braak staging and presents a feasible 
event in PD progression.  
 
1.7 Protein degradation pathways and ASYN pathology  
The ubiquitin-proteasome system (UPS) consists of ubiquitin chains attached to 
cytoplasmatic proteins that mark them for degradation, and proteasomes that consist of 
20S and 19S subunits. This 26S proteasome is barrel-shaped and breaks proteins into 
short peptides that are recycled by peptidases (Wong and Cuervo, 2010). Protein 
degradation is an ATP-dependent process and the pathway is well-defined in 
eukaryotes: Target proteins destined to be degraded are first covalently bound to 
ubiquitin via E1 enzymes in energy consuming reaction. More ubiquitin molecules follow 
with the help of ubiquitin-carriers, E2 enzymes, and ubiquitin ligases, E3 enzymes. 
Eventually these reactions lead to a ubiquitin chain that is recognized by the regulatory 
particle of the 19S proteasome subunit. Here the protein is unfolded prior to 
degradation by the 20S proteasome subunit and its components are hydrolyzed to 
amino acids and re-introduced to the cellular metabolism (Haas and Siepmann, 1997; 
Glickman and Ciechanover, 2002). The UPS is an essential cellular pathway whose 
deregulation can lead to accumulation of harmful—misfolded peptide chains, excess 
amounts or protein, and lead to pathological conditions including neurodegeneration 
(Bedford et al., 2008). 
Following the discovery of Lewy bodies staining positive for ubiquitin (Kuzuhara et al., 
1988), evidence of proteasomal dysfunction in PD was uncovered (McNaught and 
Jenner, 2001). Supporting this evidence are is a rat model of PD which is induced by 
proteasome inhibitors (McNaught and Olanow, 2006) that shows the core pathological 
features including motor deficits and degeneration of dopaminergic neurons. 
Proteasome activity is also reduced in toxin-induced models of PD, namely following 
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exposure of cells and animals to rotenone and MPTP (Fornai et al., 2005; Betarbet et al., 
2006; Chou et al., 2010).  
The autophagy-lysosomal pathway encompasses all degradation processes whose 
ultimate target is the lysosome or lysosomal membrane. Lysosomes are membrane-
enclosed vesicles that contain a variety of cellular proteases, hydrolases and maintain an 
acidic pH (Cuervo and Dice, 1998). Autophagy is a process intimately linked to the 
functioning of the lysosome, as autophagic vesicles will fuse with the lysosomal 
membrane in order for the hydrolases to digest the content of the autophagosome. It is 
the process by which especially cytosolic proteins are degraded and can be roughly 
structured into macroautophagy, microautophagy, and chaperone mediated autophagy 
(CMA) (Mizushima et al., 2002). During macroautophagy, a double membrane forms 
around proteins or organelles, and the resulting vesicle is called the autophagosome 
(Marzella et al., 1981; Mizushima et al., 2002). It is induced by starvation or injury and 
acts in conjunction with autophagy-related-genes (Atgs), which regulate the different 
pathways. The autophagosome will eventually fuse with a lysosomal membrane and 
release its content into the lysosome (Cuervo and Dice, 1998; Wong and Cuervo, 2010). 
The small GTPase Rab7 is a key regulatory factor in this process (Jäger et al., 2004). 
Meanwhile, microautophagy describes the direct absorption of cytoplasmatic proteins 
into the lysosome via invagination of the membrane (Marzella et al., 1981). CMA on the 
other hand presents a selective and specific pathway that involves heat shock complex 
(hsc) 70. Hsc70 is a chaperone, that will transport a protein to the lysosome if it 
encounters an hsc70 –recognition site on the protein in question (Cuervo and Dice, 
1998; Bandyopadhyay et al., 2008). The whole complex is then transported to and 
admitted into the lysosome via receptor binding, where the protein is unfolded and 
degraded (Cuervo and Dice, 1998). 
ASYN degradation seems to follow both pathways, although degradation of the protein 
is not fully understood in pathological conditions. However, mounting evidence suggests 
that both the UPS as well as the autophagic pathway are involved (Kuzuhara et al., 1988; 
Webb et al., 2003; Cuervo et al., 2004; Lee et al., 2004; Cookson, 2005; Qiao et al., 2008; 
Sevlever et al., 2008; Klucken et al., 2012; Petroi et al., 2012; Crabtree et al., 2014).  
LBs are ubiquinated, indicating that they might be subject of degradation by UPS 
(Kuzuhara et al., 1988; Cookson, 2005). Furthermore, Parkin, an E3 ligase, is a gene 
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associated with early onset of PD upon mutation and is also localized in LBs (Kitada et 
al., 1998; Schlossmacher et al., 2002) 
ASYN degradation by the lysosomal pathway may either present a parallel or an 
alternative mode of clearance. Autophagy-induction by the drug rapamycin leads to 
increased degradation of ASYN (Webb et al., 2003), while ASYN mutation impairs CMA 
(Cuervo et al., 2004). After translocation to the lysosome, the lysosomal protease CatD 
was shown to degrade wt ASYN (Qiao et al., 2008; Sevlever et al., 2008; Crabtree et al., 
2014). Previous studies further showed oligomeric ASYN in cell culture (Lee et al., 2004) 
and aggregates in yeast, a cell model, as well as patient brains (Klucken et al., 2012; 
Petroi et al., 2012) to be degraded by the lysosome and vacuole respectively. CatD is 
proteinase located in the lysosome requiring pH ranges from 3.5-5, which is synthesized 
as an inactive precursor protein called Procathepsin D (Hasilik et al., 1982; Fusek and 
Vetvicka, 2005). Only upon association with the lysosome and maturing to its mature 
form by cleavage is CatD functional (Hasilik et al., 1982; Fusek and Vetvicka, 2005; Guha 
and Padh, 2008). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a well-known 
substrate of the lysosome (Aniento et al., 1993) and can be used, alongside CatD, to 
assess lysosomal function. However, due to its surface cysteines, GAPDH is redox 
sensitive and prone to form aggregates (Nakajima et al., 2007). The same study found 
GAPDH aggregation to be promoted by β-amyloid.  
A failing or overwhelmed degradation system may not be causative if PD, but can thus 
be considered a contributing factor. 
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2. Aim of this study 
 
The objective of this study was to investigate the mutual effects between ASYN and 
intracellular trafficking pathways. For this purpose we screened a library of EGFP tagged 
Rab GTPases in a cellular model that displays the formation of intracytoplasmatic ASYN 
inclusions. We identified pathways impacted by ASYN inclusion formation and compared 
these findings with the expression of non-inclusion prone ASYN in the same cells. We 
further investigated whether Rab GTPases of the selected pathway had an influence on 
ASYN inclusion formation or cellular ASYN distribution. This study examined ASYN 
secretion and toxicity in the presence and absence Rab GTPase overexpression. 
Afterwards we compared these findings in both our employed models. Finally, we 
analysed the identified pathways in a mouse model of ASYN pathology. 
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3. Materials and Methods 
Unless indicated otherwise, materials were purchased at Carl Roth GmbH (Karlsruhe, 
Germany) or Sigma Aldrich (St. Louis, MO, USA).  
3.1 Mice 
Animal care was conducted in house, according to institutional guidelines with a 12 h 
light / 12 h dark cycle and ad libitum access to food and water. Genotypes of Thy1-aSyn 
were determined prior to start of the experiment via polymerase chain reaction (PCR) 
from DNA isolated from tail tissue. Only male mice were used for experiments as the 
ASYN transgene was inserted on the X-chromosome and random X-inactivation might 
otherwise interfere with transgene expression (Rockenstein et al., 2002; Chesselet et al., 
2012; Magen et al., 2012). Thy1-ASYN of 13 weeks, 26 weeks and 39 weeks were 
obtained and sacrificed by cervical dislocation. Wt littermate controls were used for all 
experiments. Cortex (CTX), Hippocampus (HC), Midbrain (MB) and Striatum (STR) were 
isolated for analysis of protein expression. 
3.2 Molecular Biology Methods 
3.2.1 Transformation of Escherichia coli DH5α  
Competent E. coli cells were thawed on ice. 0.5 µg/µl of plasmid were added to the 
competent cells and incubated on ice for 30 minutes. Each sample was heat-shocked at 
42° C for 30 seconds and incubated on ice for 2 minutes. 250 µl of SOC-Medium was 
added to each sample and incubated for 1 hour at 37° C while horizontally shaking at 
600 rpm (Thermomixer comfort, Eppendorf, Hamburg, Germany). For high yield 
expression, 150 ml LB medium were inoculated, supplemented with 100 mg/ml 
Kanamycin or 200 mg/ml Ampicillin. For low yield expression, 5 ml LB medium were 
inoculated, supplemented with 100 mg/ml Kanamycin or 200 mg/ml Ampicillin. 
3.2.2 Plasmid Isolation 
3.2.2.1 Small Scale Plasmid Isolation 
Plasmids were purified with the Invisorb Spin Plasmid Mini Two (STRATEC Biomedical 
AG, Birkenfeld, Germany) kit according to the manufacturer's instructions. 
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3.2.2.2 Large Scale Plasmid Isolation 
Plasmids were purified with the NucleoBond Xtra Midi (Macherey & Nagel, Düren, 
Germany) kit according to the manufacturer's instructions. 
3.2.3.3 Agarose Gel Electrophorersis 
All samples were brought on a 1% agarose gel for plasmids or 2% agarose gel for PCR 
products from tail tissue and were run at 120 V. GeneRuler 1 kb DNA Ladder (Fermentas, 
Thermo Scientific, Waltham, MA, USA) was used as standard. 
3.2.4 Polymerase Chain Reaction (PCR) 
PCR was conducted for genotyping of animals. Tail tissue was digested by overnight 
incubation in 2.5 mg/ml Proteinase K. DNA was extracted via isopropyl ethanol 
precipitation. PCR sample preparation utilized 10x sample buffer (Genecraft, Cologne, 
Germany), dNTPs, MgCl2, Taq Polymerase (Genecraft, Cologne, Germany), with primers 
Thy1 209F (CTGGAAGATATGCCTGTGGA) and Thy1 211R (GAGGAAGGACCTCGAGGAAT). 
Reactions were run with the Eppendorf Master Gradient Cycler with 2-step PCR yielding 
a 110 bp product. 
 
3.3 Cell Culture 
Human neuroglioma H4 cells were maintained in Dulbecco's Modified Eagle Medium 
(DMEM; PAN-Biotech GmbH, Aidenbach, Germany) supplemented with 10% fetal calf 
serum (FCS; PAN-Biotech GmbH, Aidenbach, Germany) and 1% Penicillin/Streptamycin 
(PAN-Biotech GmbH, Aidenbach, Germany) at 37° C and 5% CO2.  
For in vitro experiments, cells were routinely plated 24 h prior to use at a density of 
5*104 cells/ml. Cell count was determined using a Neubauer counting chamber.  
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3.4 H4 Cell Transfection 
3.4.1 Metafectene 
H4 cells plated 24 h prior to transfection a density of 5*104 cells/ml. Transfection was 
conducted according to manufacturer's instructions at a ratio of DNA:Metafectene 
(Biontex Laboratories GmbH, Planegg, Germany) of 1:2.  
3.4.2 Calcium-Phosphate Transfection 
H4 cells plated 24 h prior to transfection a density of 5*104 cells/ml. Several hours 
before transfection, fresh medium was supplied. Transfection was conducted in 6-well 
multiwell plates (Corning Life Science, Corning, NY, USA), 12-well multiwall plates 
(Corning Life Science, Corning, NY, USA) on coverslips coated with 0.1% gelatine (VWR, 
Radnor, PA, USA) or 10 cm cell culture dishes (Corning Life Science, Corning, NY, USA). 
Table 2 shows the amounts of solutions for different well sizes. To transfect, 1xHBS (25 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 140 mM NaCl, 5 mM 
KCl, 0.75 mM Na2HPO4*2H2O, 6 mM Dextrose, pH 7.1) was mixed with appropriate 
amounts of DNA. Right after, 2.5 M CaCl2 was added and mixed again immediately. The 
mixture was incubated for 20 min before being added dropwise to the cells. The plate or 
dishes was rocked gently to mix transfection reaction with medium. After overnight 
incubation, medium was changed for full medium. Samples for further experiments 
were taken 48 h after transfection. 
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Table 2: Overview of CaPO4 transfection reaction for different culture sizes 
Format Culture Media Transfection 
Media 
1x HBS 2.5 M CaCl2 
12 well 1 ml 600 µl 36 µl 2.1 µl 
6 well 2 ml 1.5 ml 86 µl 5.1 µl 
10 cm 10 ml 8 ml 500 µl 30 µl 
 
3.5 Protein Chemistry 
3.5.1 Immunocytochemistry 
A list of primary and secondary antibodies can be found in Table 3. 
H4 cells were fixed 48 h after transfection with 4% PFA in PBS for 20 min at RT. After 
washing once with 1x PBS, cells were permeabilized for 20 min with 0.1%-0.5% Triton X-
100 at RT. After blocking for 1 h with 1.5% bovine serum albumin (BSA; NZytech, Lisbon, 
Portugal), samples were incubated with primary antibody diluted 1:500-1:2000 in 1.5% 
BSA, either 3 h at RT or over night at 4° C. Secondary antibody diluted 1:2000 in 1.5% 
BSA was added after washing three times 5 min with PBS for 2 h at RT. Samples were 
washed three times 5 min with PBS prior to incubation with Hoechst 33258 (Molecular 
Probes, Eugene, OR, USA) 1:5000 in PBS for 5 min. If immunocytochemistry was 
conducted on cover slips, these were subsequently mounted with Mowiol 4-88 
(Calbiochem, Merck Millipore, Darmstadt, Germany). Samples were visualized with Leica 
DMI 6000B (Leica Camera, Solms, Germany).  
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Table 3: Primary and secondary antibodies used in immunocytochemistry 
Antibody Manufacturer Order No Dilution 
Primary Antibodies 
Purified Mouse Anti-α-Synuclein BD Bioscience 610787 1:2000 




Alexa Fluor 488 Donkey anti-mouse 
IgG 
Molecular Probes A21202 1:2000 
Alexa Fluor 555 donkey anti-mouse IgG Molecular Probes A31570 1:2000 
Alexa Fluor 488 donkey anti-rabbit IgG Molecular Probes A21206 1:2000 
Alexa Fluor 555 donkey anti-rabbit IgG Molecular Probes A31572 1:2000 
 
3.5.3 Solubilisation of Proteins and Protein Quantification 
Following transfection, cells were solubilised 48 h later (unless indicated otherwise) with 
radioimmuniprecipitation assay (RIPA) buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1% 
Sodium-Dodecyl-Sulphate (SDS), 1% Nonidet P40, 0.5% Sodium-Deoxycholate, α-
complete (La Roche, Basel, Switzerland)). Cell lysates were centrifuged 15 min at 10,000 
g (Sigma 1-15 K, Sigma Aldrich Co. LLC, St. Louis, MO, USA) and supernatant was 
transferred into a new 1.5 ml reaction tube.  
Brains were lysed in animals lysis buffer (250 mM Sucrose, 50 mM Tris pH 7.5, 1 mM 
EDTA, 5 mM MgCl2, 5 mM KCl, 12 mM Sodium-Deoxycholate, 1% Triton X-100, α-
complete protease inhibitor cocktail (La Roche, Basel, Switzerland)) using Percellys 24 
homogenisator (bertin technologies, Montigny-le-Bretonneux, France). Afterwards 
lysates were centrifuged 10 min at 4° C and 10,000 g. The supernatants were transferred 
into a fresh tube and proteins content was quantified. 
Protein quantification was done on the basis of Bradford's assay for rapid protein 
quantification (Bradford, 1976). In short, 1 µl of cell lysate was added to 49 µl of sterile 
water and 150 µl of Protein Assay Dye Reagent Concentrate (Bio-Rad Laboratories, Inc., 
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Hercules, CA, USA). Absorbance at 595 nm over 450 nm was measured using the Infinite 
M200 PRO (Tecan Ltd., Maennedorf, Switzerland) plate reader. All samples were 
measured in triplicate.  
3.5.4 Western Blot Analysis 
Detection of proteins on immunoblots was performed to detect ASYN, Rab GTPases 
fused to EGFP, untagged Rab7, CatD, β-actin and GAPDH. 
3.5.4.1 SDS-PAGE 
Cellular lysates or brain samples were separated by sodium dodecylsulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions in 12%-15% 
separating gels with 7.5% stacking gels (Acrylamide/Bis-acrylamide ratio 37.5:1 (Carl 
Roth GmbH, Karlsruhe, Germany), 0.01 % SDS in ddH2O, 0.1 % 
tetramethylethylenediamine (TEMED), and 1 % ammonumpersulfat (APS)). 40 µg of 
sample for cell lysates or 20 µg of sample for brain lysates were prepared with five time 
Laemmli buffer (250 mM Tris pH 6.8, 10% SDS, 1.25% Bromphenol Blue, 5% β-
Mercaptoethanol, 50% Glycerol) and incubated 5 min at 96° C. Samples were loaded 
onto gel together with 5 µl PageRuler Plus Prestained Protein Ladder (Perbio Science 
Deutschland, Bonn, Germany). Electrophoresis was performed in one time SDS-Running 
Buffer (125 mM Tris, 960 mM Glycine) for 90 min at 120 V in Bio-Rad Mini-Protean 3 
Mini Vertical Electrophoresis System (Bio-Rad Laboratories, Inc., Hercules, CA, USA).  
3.5.4.2 Transfer of Proteins to Nitrocellulose Membrane 
Subsequent to SDS-PAGE, sandwich tank Western Blot was performed by transferring 
proteins from SDS matrix to Protean nitrocellulose transfer membrane (Schleicher & 
Schuell Bioscience GmbH, Dassel Germany) using Bio-Rad Mini-Protean 3 Mini Trans-
Blot module (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The sandwich was 
assembled with blotting paper (Schleicher & Schuell Bioscience GmbH, Dassel Germany) 
and membrane pre-soaked in one time transfer buffer (25 mM Tris, 192 mM Glycine, 
20% Methanol). Transfer was conducted at 300 mA for 90 min.  
3.5.4.3 Immunodetection 
A list of primary and secondary antibodies used can be found in Table 4. 
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After protein transfer, nitrocellulose membranes were blocked with 5% milk or 5% BSA 
in tris-buffered saline (TBS) to remove unspecific signal for 1 h at RT. Afterwards, 
membrane was in primary antibody (Table 4) diluted in 5% BSA in TBS 1:1000-1:5000 
supplemented with sodium acid for preservation purposes, overnight a 4° C. 
Membranes were washed three times for 5 min in TBS supplemented with 0.1% Tween 
(TBST). Afterwards, membranes were incubated for 30-45 min in secondary antibody 
conjugated with HRP (Table 4) diluted 1:20,000 in TBS. Membranes were washed three 
times for 5 min in TBST. Afterwards, membranes were visualized using AlphaImager 
(Alpha Innotech, San Leandro, CA, USA) or Fusion Fx (Vilber Lourmat, Marne-la-Vallée, 
France) with Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore, 
Billerica, MA, USA). Membranes were stripped or dried at RT and stored for potential 
future use. Densitometric quantification was conducted using Image J 1.49m, distributed 
by the National Institute of Health, USA. 
 
Table 4: Primary and secondary antibodies used in Western blot analyses 
Antibody Manufacturer Order No Dilution 
Primary Antibodies 
Purified Mouse Anti-α-Synuclein BD Bioscience 610787 1:2000 
Cathepsin D Antibody (C-20) Santa Cruz Biotechnology sc-6486 1:5000 
GAPDH Antibody Thermo Scientific PA1-988 1:2000 
Rab 7 Antibody (H-50) Santa Cruz Biotechnology sc-10767 1:1000 
Monoclonal Anti-ß-Actin antibody Sigma-Aldrich A5441 1:10,000 
Secondary Antibodies 
ECL Mouse IgG, HRP-Linked  GE Healthcare NXA931 1:20,000 
ECL anti rabbit IgG, HRP-Linked  GE Healthcare NA934V 1:20,000 
HRP-conjugated donkey anti-goat Jackson Immunoresearch 705-035-003 1:20,000 
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3.5.4.4 Membrane Stripping 
To remove primary and secondary antibody for detection of more proteins, membranes 
were stripped by incubating them in stripping buffer (200 mM Glycine, 500 mM NaCl, pH 
2.8) for 15-20 min. Subsequently, membranes were re-blocked and antibody incubation 
could proceed. 
3.5.5 Immunodetection of ASYN with Sandwich ELISA 
For a list of antibodies employed see Table 5. 
In order to detect ASYN released by cells into the extracellular space, we performed 
direct enzyme-linked immunosorbent assay (ELISA), so called sandwich ELISA (compare 
Figure 5). One day prior to experiment, a 96 well plate, High Bind, polystyrene, flat 
bottom (Corning, Corning, NY, USA) was coated with 1 µg/ml capture antibody against 
ASYN diluted in PBS (PAN-Biotech GmbH, Aidenbach, Germany). The plate was 
incubated overnight at 4°C covered with laboratory film. The next day the plate was 
washed five times using the Multidrop Combi (Thermo Scientific, Waltham, MA, USA) 
with ELISA washing buffer (0.0325 mM NaH2PO4*H2O, 24.5 mM Na2HPO4*2H2O, 150 mM 
NaCl, 0.1% Tween-20, pH 7.5). The plate was blocked for at least 2 h at RT with ELISA 
blocking buffer (PBS, 0.1% BSA) shaking at 900 rpm on the OS-500 plate shaker (VWR, 
Radnor, PA, USA). Sample standards were prepared with recombinant monomeric ASYN 
(with thanks to Dr. Anna Villar-Piqué) in ELISA incubation buffer (PBS, 0.01% BSA, 0.1% 
Tween-20) in duplicate or triplicate at concentrations of 0.001 nM, 0.01 nM, 0.1 nM, 1 
nM, 2.5 nM, 5 nM, 10 nM, 25 nM, 50 nM, 75 nM and 100 nM. After blocking, plate was 
washed 5 times with ELISA washing buffer. Sample standards and 200 µl sample were 
loaded onto the plate, samples were loaded either in technical duplicates or triplicates. 
The plate was incubated for 2 h at RT shaking at 900 rpm on the OS-500 plate shaker 
(VWR, Radnor, PA, USA) covered in laboratory film. Afterwards, plate was washed 5 
times times with ELISA washing buffer. An α/β/γ-synuclein antibody was used as primary 
detection antibody and it was prepared at 1 µg/ml in ELISA incubation buffer. The plate 
was incubated 1 h at RT shaking at 900 rpm covered in laboratory film. Afterwards, plate 
was washed 5 times times. HRP-conjugated anti-rabbit antibody was used for secondary 
detection at a concentration of 1:10,000 diluted in ELISA incubation buffer. The plate 
was incubated for 45-60 min at RT shaking at 900 rpm covered in laboratory film. 
Subsequently, the plate was washed 5 times with ELISA washing buffer. Room tempered 
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TMB Chromogen Solution (Life Technologies, Carlsbad, CA, USA) was used as HRP 
substrate and 100 µl/well were incubated with the samples. The reaction was stopped 
after 1-30 min, when the blue color had sufficiently developed but before signal 
saturation, with 1 M sulfuric acid. The absorbance at 450 nm was measured using the 
Infinite M200 PRO (Tecan Ltd., Maennedorf, Switzerland). Calculations were conducted 
by nonlinear regression curve fit with sigmoidal dose-response equation using Prism 
4.03.  
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Table 5: Antibodies used in sandwich ELISA 
Purpose Antibody Manufacturer Order No Dilution 
Capture Human Synuclein-alpha MAb 
(Clone 189105)  







sc-10717 1 µ/ml 
Secondary 
Detection 
ECL anti rabbit IgG, HRP-
Linked  


















To detect a shift 
in particulate size of ASYN, SEC was performed using high performance liquid 
Figure 5: Schematic of sandwich ELISA. A microtiter plate is coated with capture antibody targeted against 
epitope of protein of interest. The target protein binds to the capture antibody upon incubation. A second 
antibody targeted against another epitope is employed as primary detection antibody. A third antibody 
targeted against the primary detection antibody and conjugated with horse radish peroxidase (HRP) is used for 
detection. The HRP catalyzes the TMB substrate into a blue precipitate. 
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chromatography (HPLC). H4 cells were grown in 10 cm cell culture dishes dishes and 
transfected with a total of 25 µg ASYN, GFP, Rab5 and Rab7 constructs. 48 h after 
transfection, cells were collected in phosphate lysis buffer (PBS, 0.5% Triton X-100), 
freshly supplemented with protease inhibitor α-complete (La Roche, Basel, Switzerland) 
and centrifuged for 15 min at 10,000 g to remove cellular debris. After total amount of 
protein was determined, 2-3 mg total protein in a volume of 500 µl was filtered through 
a 0.45 µm Spin-X centrifuge filter and then loaded onto a Superose 6 (Superose 6 
10/300GL, GE Healthcare Life Science, Sweden) column with subsequent performance of 
HPLC (Äkta Purifier 10, GE Healthcare Life Science, Sweden) in 50mM ammonium 
acetate pH 7.4 buffer with a flow rate of 0.5 ml/min (Äkta Purifier operation was 
conducted by Tomás Lopes da Fonseca). Fractions of 500 µl were collected and stored at 
4° C up until 24 h after collection.  
3.5.6.1 Dot Blot 
All HPLC samples were boiled for 10 min at 95° C at 650 rpm and then spun down briefly 
at 10,000 g and 4° C. Samples were loaded fully into two rows of a 96 well Dot Blot 
machine constructed in house. A vacuum pump was used to suck sample through a 0.2 
µm pore size Protean nitrocellulose membrane (Schleicher & Schuell Bioscience GmbH, 
Dassel, Germany). The membrane was subsequently blocked with 5% skim milk in TBS to 
prevent unspecific staining for 1 h. Membranes were incubated with primary antibody 
diluted in 1% skim milk in TBS or 5% BSA in TBS to 1:2000 overnight at 4° C. Membranes 
were washed three times with TBST. Subsequently, membranes were incubated with 
secondary antibody diluted 1:10,000 in TBS. Afterwards, membranes were visualized 
using Fusion Fx (Vilber Lourmat, Marne-la-Vallée, France) with Immobilon Western 
Chemiluminescent HRP Substrate (Merck Millipore, Billerica, MA, USA). 
3.6 Cell Viability 
48 h after transfection, culture supernatant from 6-well multiwell plates was collected 
and cytotoxicity was determined via release of LDH into the culture medium with the 
Cytotoxicity Detection Kit (LDH) (La Roche Ltd, Basel, Switzerland). Basic LDH release was 
measured from vehicle-treated controls for background correction. Total LDH release 
was determined by incubating cells in culture medium supplemented with 2% Triton X-
100. Absorbance of 96 well plate with samples was measured at 490 nm with the Infinite 
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M200 PRO (Tecan Ltd., Maennedorf, Switzerland). Experimental values were calculated 





4.1 Screen of Rab GTPase library with model of ASYN inclusion 
formation identifies putative targets 
The family of Rab GTPases are integral parts of the intracellular vesicle trafficking 
machinery with a variety of tasks and up to four isoforms for proteins. Although some 
members of this family could already be identified to be involved in PD and be 
dysregulated with ASYN pathology, a comprehensive screen with a single model was 
missing as of the conception of this study. In order to address this, we screened a Rab 
GTPase library containing almost all human Rab GTPases (a kind gift from Prof. Mikael 
Simons) and their isoforms in the human H4 neuroglioma cell line. These we 
cotransfected with a previously described variant of ASYN that is modified at the C-
terminus (SynT), rendering it prone to inclusion formation (Figure 7B). This model has 
the advantages of forming LB-like inclusions in a cellular context (McLean et al., 2001; 
Klucken et al., 2012; Yin et al., 2014). All Rabs are EGFP tagged and SynT was visualized 
via immunocytochemistry (Figure 7B). All experiments were evaluated using 
epifluorescence microscopy and were analyzed for changes either in the presentation of 
the Rab protein or the SynT. Each experiment was accompanied by a control that 
expressed an empty vector alongside the target protein, Rab GTPase or SynT. Table 6 
summarizes the findings, which include both changes to the intracellular distribution of 
various Rab proteins as well as to the presentation of the SynT inclusions. All 
experiments were conducted a total of three times to exclude handling errors, but 
evaluation initially was of qualitative, rather than quantitative nature. All observed 
effects were consistent in all experiments. Each Rab protein has a distinct pattern of 
localization. Rabs located to the membrane of the same compartment have a similar 
distribution pattern, but neither exactly the same. This was also true for isoforms. The 
pattern of distribution and the localization of the Rabs changed dramatically upon 
coexpression of SynT. Generally, many Rab GTPases colocalized at least partially with 
ASYN positive inclusions and lost their distinct distribution pattern, instead they took on 
a diffuse presentation throughout the cytoplasm. Rab7 was an intriguing exception here, 
as it showed no colocalization with inclusions in any of the experiments. Contrary to 
observations made of the Rabs, only few effects on SynT could be determined: 
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coexpression with Rab7 yielded an apparent increase in inclusion formation and no 
localization with the inclusions, while coexpression of Rab8A and SynT resulted in fewer 
condensed nuclei, hinting at a decrease in toxic effect and Rab35 seemed to shift SynT 





Table 6: Rab GTPase library screen reveals effects of ASYN inclusion formation on intracellular trafficking 
proteins 
Rab GTPase Organelle Localization / 
Target Membrane 
(Hutagalung and Novick, 
2011) 
Effect on Rab 
distribution with SynT 
coexpression 
Effect on SynT 
inclusions with 
Rab coexpression 









Rab2A ER, ER-Golgi 
intermediate 
department, Golgi 





Rab2B ER, ER-Golgi 
intermediate 
department, Golgi 





Rab3A Secretory vesicle, plasma 
membrane 
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Rab8A Secretory vesicle, plasma 
membrane 
Colocalization with 




Rab8B Secretory vesicle, plasma 
membrane 



















Rab12 Golgi, secretory vesicle Diffusion through the 
cytoplasm 
No effect 
Rab13 Cell/tight junctions, TGN, 
recycling endosome 





Rab15 Early/sorting endosome Diffuse presentation in 









Rab18 Golgi, lipid droplets Partial maintenance of 
localization 
No effect 
Rab20 Golgi, endosome Diffuse presentation in 




Rab22A Early endosome Diffusion through the 
cytoplasm 
No effect 













Rab26 Secretory granules Partial maintenance of 
localization 
No effect 















Rab30 ER, Golgi Partial maintenance of 
localization 
No effect 





Rab32 Mitochondria Maintenance of 
localization 
No effect 


















SynT to the 
nucleus/nuclear 
envelope 
Rab36 Golgi Maintenance of 
localization 
No effect 
Rab37 Secretory granules Diffuse presentation in 




Rab38 Melanosomes Diffuse presentation in 









Rab40B Golgi, ER Diffuse presentation in 




Rab40C Golgi, ER Relocalization to the 
vicinity of the nucleus 
No effect 
Rab43 ER, Golgi Diffuse presentation in 
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4.2 Rab GTPases colocalize with ASYN inclusions and modulate their 
formation  
Cell survival is a crucial parameter in the investigation of neurodegenerative diseases 
and Rab8A was shown in the past to have a beneficial effect in regards to ASYN 
mediated toxicity (Gitler et al., 2008). Rab8A is located in the TGN and at tubular 
recycling endosomes (Figure 6A), regulating exocytosis and other sorting events. We 
could show that Rab8A colocalized with SynT mediated inclusions (Figure 6B) and 
overexpression of Rab8A resulted in an increase of cells with inclusions by 30% (Figure 
6C). At the same time, the S129 phosphomimetic mutant of SynT, S129D, increased the 
number of inclusions per cell (Figure 6D) and a block of phosphorylation with the S129A 
mutation resulted in more cells without aggregates (Figure 6D). (Assessment of inclusion 




Figure 6: Rab8A modulates ASYN inclusion formation cells. (A) Representative live cell image of H4 cells 
expressing Rab8A. The arrowhead marks typical structure of tubular endosomal compartments. (B) Rab8A 
loses its localization and instead colocalizes with SynT mediated inclusions. (C) The presence of the 
phosphomimetic variant S129D of SynT increases the number of inclusions per cell but not the total 
percentage of cells with aggregates. On the other hand the S129A SynT mutant showed a reduction in the 
percentage of cells with inclusions. ** p ≤ 0.01, *** p ≤ 0.001 Two-way ANOVA. Scale bar: 20 μm. (Statistics 
originally published in 2014 (Yin et al., 2014).) 
 
We selected Rab5A and Rab7 because they occupy the same target membrane at 
different maturation stages of the vesicle, the endosome, albeit at different domains. 
Both are important regulators of trafficking steps in the endocytic-lysosomal pathway 
and are key proteins for the progression through the degradation pathway. Both have a 
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similar, yet distinctly different distribution pattern in the cell (Figure 7A). Rab5A is 
located at early endosomes, also called sorting endosomes, where it mediates fusion of 
endocytic vesicles with the early endosome as well as helps sorting cargo into different 
endosomal compartments. The decision about the fate of internalized cargo is made at 
the sorting endosome and can enter either the endocytic recycling or endocytic 
degradation pathway. Overexpression of Rab5A leads to enlarged endosomes. Rab7 is 
an identifier of late endosomes and lysosomes—vesicles that maintain a mild to strong 
acidic environment—and mediates progression through the autophagic pathway. 
Overexpression of Rab7 leads to more and enlarged lysosomes that are often localized 
in the perinuclear region.  
When coexpressed with SynT, the subcellular localization of EGFP-Rab5A, but not EGFP-
Rab7, changed in the presence of ASYN positive inclusions (Figure 7C). EGFP-Rab5A 
colocalized with ASYN inclusions in a in a significantly stronger manner than EGFP-Rab7 
(Figure 7D). Next we determined the percentage of cells with ASYN inclusion formation 
in control conditions and with co-expression of EGFP-Rab5A or EGFP-Rab7. In 
comparison we found no significant difference between control conditions and co-
expression with EGFP-Rab5A, although a trend could be established towards an increase 
in inclusion formation (Figure 7E). With EGFP-Rab7 co-expression, significantly more 





Figure 7: ASYN inclusions lead to mislocalization of trafficking markers and Rab7 modulates inclusion 
formation. (A) Rab5A and Rab7 distribution in the cell. Both Rab proteins are located at their target 
membranes with vesicular distribution. (B) ASYN inclusion formation due to a modified C-terminus, termed 
SynT. (C) Expression of SynT with Rab GTPases. Rab5A is localized away from its target membrane and 
localizes with ASYN inclusions. Rab7 does not colocalize with ASYN inclusions. Insets show blow up images 
of regions of interest (ROI) framed in white. (D) Rab5A shows higher colocalization with ASYN inclusions 
than Rab7. (D) Rab7 increases the percentage of cells showing inclusions. All statistical analysis are from 
n=3-4 independent experiments and represent mean ± S.D.; * p ≤ 0.05 One-tailed paired t-test, *** p ≤ 
0.001 Two-tailed paired t-test, Scale bar: 10 µm. 
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Expression of wt ASYN lacks inclusion formation in the way we observed with SynT 
(Figure 7B, Figure 8A). Instead, ASYN is distributed throughout the cytosol with little to 
no obvious structural features (Figure 9A). We also see no formation of inclusions 
anywhere in our investigated cells when we co-express Rab GTPases (Figure 8B). 
However upon investigation of subcellular localization under these conditions, we could 
determine a strong trend towards a far more structured presentation of ASYN than in 
our previous observations (Figure 8B). These structures look not unlike vesicles. At the 
same time, investigations into the subcellular localization showed a strong colocalization 
with both EGFP-Rab5A and EGFP-Rab7 (Figure 8B, C). We could further show that while 
ASYN colocalized with EGFP-Rab5A, the effect with EGFP-Rab7 co-expression was 









Figure 8: Wild type ASYN vesiculates with the overexpression of Rab GTPases. (A) Wt ASYN is distributed in 
the cytosol with few structural features. (B) Wild type ASYN presents in vesicular structures that colocalize 
with Rab5A and Rab7 when either is overexpressed. Insets show blow up images of ROI framed in white. (C) 
Native ASYN colocalizes stronger with Rab7 positive structures than Rab5A positive structures. All statistical 
analysis are from n=3-4 independent experiments and represent mean ± S.D.; *** p ≤ 0.001 Two-tailed paired 
t-test, Scale bar: 10 µm 
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4.3 ASYN particulate size is modulated by endosomal Rab GTPases 
The vesiculation of wt ASYN in the presence of endosomal Rab GTPases is an 
unexpected side effect we observed during the expression of Rab5A and Rab7 alongside 
ASYN (Figure 8B). We were curious whether this meant a change in ASYN conformation. 
Generally, ASYN is a natively unfolded monomer with membrane binding capabilities, 
although it has been argued that ASYN presents as a tetramer in an intracellular context 
(Bartels et al., 2011; Wang et al., 2011). However, different genetic contexts might be 
able to alter the organization state of proteins. 
To investigate the particulate size of ASYN, we employed SEC via a high performance 
liquid chromatography (HPLC) machine and a dot blot apparatus made in house. A 
schematic can be seen in Figure 9A. Blotting the A1-D11 fractions revealed a size shift of 
ASYN from the C3-C6 fractions, corresponding to 44 kDa to 17 kDa (Figure 9B), which is 
concurrent with the monomeric fraction in our hands, to fractions spanning B1 to C7 
fractions in the presence of EGFP-Rab5A (Figure 9C). These correspond to high 
molecular weight oligomers of up to 670 kDa or above. In the presence of EGFP-Rab7, 
we could observe a similar shift in size, although these concentrated in the upper B and 
C fractions (Figure 9D). Figure 9E shows a graphical representation of the Dot Blots, and 
a clear shift is visible from the lower molecular weight fractions when ASYN is expressed 





Figure 9: Rab GTPases change the particulate size of ASYN. (A) Size schematic of the HPLC fractions, blue: 
Fraction A1-A15, void volume; green: Fraction B1-B15, 670 kDa; yellow: Fraction C1-C15, 150 kDa – 1.35 
kDa. (B) Dot Blot of control condition, ASYN and EGFP, only monomeric ASYN can be found in the C fraction. 
(C) ASYN and Rab5A coexpression, a shift to higher molecular sizes from 670 kDa to monomeric sizes. (D) 
ASYN and Rab7 coexpression lead to a shift to 670 kDa to 158 kDa. (E) Graphical representation of ASYN 
fractioning with different genetic contexts: co-expression with GFP (black), Rab5A (red) and Rab7 (green). 
Inset shows ASYN protein levels remain the same; β-actin was employed as loading control. All experiments 
are representative of n=3 independent experiments. 
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4.4 Endosomal Rab GTPases modulate ASYN secretion and toxicity, 
depending on their cellular function 
While Rab5A is not directly involved in the secretory pathway, it is an important 
mediator of the modular system of endosomes. This system includes not only the early 
and late endosome, but also the recycling endosome. Each of these compartments is the 
domain of different Rab GTPases with different functions, although all of them are 
connected to the sorting endosome. Hence, manipulating early endosomal markers in 
ASYN overexpressing cells might lead to an effect on secretion.  
For this purpose, human H4 neuroglioma cells were cotransfected with either SynT or wt 
ASYN, as well as EGFP-Rab5A or EGFP-Rab7. To investigate whether any observed effects 
were a direct results of the overexpression of the Rab protein, we also transfected the 
constitutive active, GTPase activity deficient mutants EGFP-Rab5A Q79L and EGFP-Rab7 
Q67L as well as the dominant native, GDP-bound mutants EGFP-Rab5A N133I and EGFP-
Rab7 T22N (all mutants generous gifts of G. Schiavo and C. Bucci) in parallel. The 
experiments were performed utilizing a Sandwich ELISA, the principal idea of which is 
displayed in Figure 5. Briefly, a high binding microtiter plate is coated with a capture 
antibody, which is highly specific for an epitope on ASYN. The sample is incubated with 
the plate before a second antibody is used for primary detection. Lastly, a secondary 
detection antibody targeted against the primary detection antibody coupled with horse 
radish peroxidase is used for detection. An enzymatic substrate reveals protein levels in 
the sample in a colorimetric manner. The resulting standard curve can be seen in Figure 
10A. 
Co-expression of EGFP-Rab5A Q79L and wt ASYN leads to an increase in secretion 
(Figure 10B), indicating accelerated sorting activity from the early endosome into the 
recycling pathway. This is confirmed by a sharp drop in secretion with the co-expression 
of the dominant negative mutant, although secretion is not entirely abolished (Figure 
10B), hinting at a secondary release pathway independent of the early endosome. 
Expression of all three EGFP-Rab7 mutants along wt ASYN leads to a decrease in ASYN 
release indicative or higher protein turnover (Figure 10B) despite equal protein amounts 
(Figure 10F, G).  
Employing the inclusion model yields a sharp decrease in ASYN release with the co-
expression of the constitutive active mutant of EGFP-Rab5A, while release is almost 
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unchanged upon expression with the dominant negative mutant (Figure 10C). For EGFP-
Rab7 we once more see a decrease in ASYN release in all three mutants (Figure 10C), 
indicative of higher protein turnover or a blocked release pathway, despite equal 
amounts of protein (Figure 10F, H). 
To ensure these effects, and especially the high variances in the experiments with EGFP-
Rab5A wt, were not due to increased release of the material of dead cells into the 
medium, we performed an LDH assay. This enzymatic assay measures the concentration 
in the culture medium in a colorimetric manner. No significant differences could be 
determined between experiments and control conditions (Figure 10D, E). In our previous 
study (Yin et al., 2014) we found SynT mediated cellular toxicity decreasing significantly 
with Rab8A co-expression when compared to SynT expression alone (Figure 11A). This 
rescue was not due to altered protein levels (Figure 11B), and we could repeat this 
effect with the phospho-mutants of SynT (Figure 11). Whether this effect is related to 
altered aggregation behavior Figure 6 remains unknown (Yin et al., 2014).  
  











Figure 10: Endosomal Rab GTPases modulate secretion of ASYN but do not influence toxicity. (A) Standard 
curve for calculation of secreted protein. Table inset shows molarities and percentage of binding. (B) Fold 
change of secretion compared between native ASYN with GFP for control and expression alongside Rab5A 
and Rab7 wt and activity mutants. (C) Fold change of secretion compared between native ASYN with GFP for 
control and expression alongside Rab5A and Rab7 wt and activity mutants. (D, E) Expression of Rab GTPases 
and activity mutants with ASYN or SynT do not interfere with cell survival. (F, G, H) Expression of ASYN or 
SynT with Rab5A and Rab7 wt or constitutive active or dominant negative mutants do not change protein 
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expression. All analyses represent n=4 independent experiments and statistical data is displayed as mean ± 
S.D.; + 0.1 < p < 0.05, * p ≤ 0.05 One-tailed paired t-test. 
 
Figure 11: Rab8a rescues SynT-induced cellular toxicity. (A) Expression of SynT increases toxicity by more 
than two-fold and is rescued by co-expression of Rab8A. All data are presented relative to total cell death 
and were normalized to empty vector control. Data is presented as mean ± S.D. * p ≤ 0.05, ** p ≤ 0.01, *** 
p ≤ 0.001 Two-tailed paired t-test two-tailed paired t-test. (B) Protein expression levels remain unchanged in 
experimental conditions. β-actin as employed as loading control. Experiments represent n=3-5 independent 
experiments. (Modified, original version published 2014 (Yin et al., 2014).) 
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4.5 Lysosomal and degradation markers are dysregulated with 
constitutive ASYN expression in vivo 
Since especially Rab7 is involved in the progression through the degradation pathway 
and taking the previous findings into account, we finally investigated several markers of 
the degradation pathway in vivo. For this study, we utilized a mouse model 
overexpressing full length human wt ASYN under the murine Thy1 promoter on a C57Bl6 
background that has been developed in the laboratory of Elizier Masliah (Rockenstein et 
al., 2002). Only males were used for this study, since the ASYN transgene is inserted on 
the X-chromosome and expression of the transgene in females in all cell types is not 
guaranteed due to random X-inactivation. We initially investigated animals at 26 weeks 
of age and then selected two more timepoints at 13 and 39 weeks to represent young 
adult age and aged individuals. The mouse model overexpresses ASYN in a moderate to 
strong manner, develops proteinase K resistant ASYN inclusions and shows striatal 
dopamine loss at 14 months of age (Lam et al., 2011; Chesselet et al., 2012). To 
investigate protein expression, mice were sacrificed at the indicated age, brains were 
harvested and dissected to isolate cortex (CTX), hippocampus (HC), midbrain (MB) and 
striatum (STR). These areas were selected due to their importance to movement, 
coordination, and memory. Brain areas were lysed, immunoblotted and blots were 
stained for ASYN, Rab7, CatD, GAPDH as well as β-actin as a loading control. All data was 
analyzed for changes due to genotype (Figure 12) and afterwards also for changes in age 
progression. 
In all tested animals, expression of ASYN was strong compared to wt littermates across 
the investigated brain regions (Figure 12). Additional to ASYN, we chose three markers 
related to the lysosome and lysosomal degradation: Rab7, GAPDH, a well-known 
substrate of the lysosome, and CatD indicative of lysosomal function. All protein levels 
were normalized against β-actin, which acted as loading control and only then compared 




Figure 12: Representative immunoblots for degradation markers of transgenic animals and wt littermate 
controls at different ages. (A) Representative immunoblot of 13 week old ASYN transgenic animal and wt 
littermate control probed for Rab7, CatD, ASYN and GAPDH, as well as β-actin as loading control. (B) 
Representative immunoblot of 26 week old ASYN transgenic animal and wt littermate control probed for 
Rab7, CatD, ASYN and GAPDH, as well as β-actin as loading control. (C) Representative immunoblot of 39 
week old ASYN transgenic animal and wt littermate control probed for Rab7, CatD, ASYN and GAPDH, as 
well as β-actin as loading control. 
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In the cortex of Thy1-ASYN Tg animals, Rab7 is elevated compared to wt littermate 
controls at all three ages (Figure 13A). Increased expression of lysosomal marker Rab7 is 
therefore evident in the cortex across adulthood and into advanced age. In the 
hippocampus of ASYN transgenic mice, Rab7 expression is upregulated two-fold 
compared to littermate controls at 26 weeks of age (Figure 13A). In 13 week old animals 
we can detected a slight elevation, while in 39 week old animals, Rab7 expression is 
indistinguishable between transgenic and non-transgenic animals (Figure 13A). In the 
midbrain we can detect a similar pattern, as we can detect slight elevations of Rab7 
levels in 13 week and 39 week old animals, but we see a significant increase of Rab7 in 
26 week old animals Figure 13A. In the striatum, Rab7 levels are elevated at 13 weeks of 
age by 66% in transgenic mice (Figure 13A). In 26 week old animals, Rab7 levels are 
almost equal between transgenic and non-transgenic animals, while in 39 week old 
animals, we can detect a slight decrease of Rab7 levels in animals carrying the transgene 
compared to wt controls. 
The degradation pathway of GAPDH proceeds via the lysosome (Aniento et al., 1993), 
hence it can be used to assess lysosomal function. In cortices of 13 week old animals we 
determined an increase in GAPDH levels in ASYN transgenic animals compared to 
littermate controls (Figure 13B). Levels remain the same, if with high variances, at 26 
weeks of age, but drop below levels of littermate controls at 39 weeks of age (Figure 
13B). In the hippocampus no change in GAPDH levels is evident at 13 weeks and 26 
weeks of age, but GAPDH levels drop below those of littermate controls at 39 weeks of 
age (Figure 13B). In midbrain, GAPDH levels are unchanged between ASYN transgenic 
animals and wt littermate controls. In striatum, GAPDH levels are unchanged at 13 
weeks of age, but at 26 weeks old, GAPDH levels in ASYN transgenic animals are lower 
than in wt littermate controls (Figure 13B). At 39 weeks of age, GAPDH levels in ASYN 
transgenic animals are significantly lower than in wt control animals (Figure 13B). 
CatD is the main lysosomal enzyme responsible for ASYN degradation (Qiao et al., 2008; 
Sevlever et al., 2008; Crabtree et al., 2014). CatD is cleaved only after association with 
the lysosome, where it matures from an inactive precursor protein to the proteolytically 
active form (Hasilik et al., 1982; Fusek and Vetvicka, 2005; Guha and Padh, 2008), which 
is why it can also indicate lysosomal function. Total levels of CatD are mildly increased in 
all brain regions of transgenic animals, although the variances are very high (Figure 12, 
Figure 13C). We see a slight increase of total CatD levels in cortices of ASYN transgenic 
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mice in all ages (Figure 13C). On the other hand, levels of cleaved, mature CatD are 
elevated in cortices of 13 week old ASYN transgenic mice (Figure 13D). Levels of mature 
CatD in the cortices of 26 week old mice are not distinguishable and at 39 weeks old, 
levels of mature CatD are slightly elevated in the cortices of transgenic mice. In 
hippocampi total and cleaved levels of CatD are slightly elevated in transgenic mice at 13 
weeks and 26 weeks of age (Figure 13C, D). In 39 week old animals, levels of cleaved 
CatD drop sharply below levels in wt littermate controls, while total levels remain the 
same (Figure 13C, D). In midbrain, total levels of CatD are elevated in all ages in ASYN 
transgenic animals and significantly so at 39 weeks of age (Figure 13C). CatD cleavage 
remains unchanged in 13 weeks old transgenic animals compared to littermate controls 
but is mildly increased in 26 week old animals and significantly increased in 39 week old 
animals (Figure 13D). In the striatum, levels of total CatD remain on par between 
transgenic and non-transgenic animals and we are unable to observe a difference in the 
genotypes at any age (Figure 13C). The same is true for mature CatD and we are unable 
to observe genotypic differences, although a mild decrease in cleaved CatD levels might 
be determined (Figure 13D). 
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Figure 13: Degradation markers are dysregulated in ASYN transgenic animals. (A) Quantification of 
immunoblots for Rab7 probe, compared between ASYN transgenic and wt animals at three different ages. 
Upregulation in ASYN transgenic mice is especially clear in young and middle aged mice and decreases in 
aged animals. (B) Quantification of immunoblots for GAPDH probe, compared between ASYN transgenic and 
wt animals at three different ages. Levels are increased or equal in ASYN transgenic mice and 
downregulated in aged ASYN transgenic mice. (C) Quantification of immunoblots for total CatD, compared 
between ASYN transgenic and wt animals at three different ages. Total levels of CatD are increased in ASYN 
transgenic animals. (D) Quantification of immunoblots for mature CatD, compared between ASYN 
transgenic and wt animals at three different ages. CatD cleavage is increased in young and middle aged 
ASYN transgenic animals but decreases in aged ASYN transgenic animals when compared to wt littermate 
controls. Results are representative of n=14 individuals with mean ± S.D.; + 0.1 < p < 0.05, * p ≤ 0.05 and all 





5. Discussion  
ASYN, the main component of LBs, is a major player in PD pathology. For reasons that 
are not clearly understood, ASYN experiences a toxic gain of function upon mutation or 
increased expression. Several genetic screens have revealed gene clusters associated 
with intracellular trafficking to be effective modulators of ASYN toxicity.  
Vesicle trafficking genes were first identified as modulators of ASYN toxicity in screens 
based on the model organisms Saccharomyces cerevisiae and C. elegans (Outeiro and 
Lindquist, 2003; Willingham et al., 2003; Hamamichi et al., 2008; van Ham et al., 2008). 
Synaptic vesicle trafficking has also been identified as one of factors of neuronal 
dysfunction that arise with ASYN pathology in other studies (Nemani et al., 2010; Scott 
et al., 2010). ASYN has been shown to interact with proteins of the trafficking gene 
families of SNAREs (Chandra et al., 2005; Burré et al., 2010; Thayanidhi et al., 2010, 
2012) and Rab GTPases (Dalfó et al., 2004a, 2004b; Dalfó and Ferrer, 2005; Soper et al., 
2008, 2011; Liu et al., 2009; Sancenon et al., 2012; Chen et al., 2013). Other genetic 
screens in these organisms could show further impact on ASYN modulated toxicity by 
the overexpression of Rab GTPases (Cooper et al., 2006; Gitler et al., 2008) or show an 
influence of ASYN on cellular Rab homeostasis (Gitler et al., 2008; Soper et al., 2011). 
Recently, we could also show in our own lab that ASYN interacts with Rab GTPases in 
vivo outside of a transgenic of a pathological context (Chutna et al., 2014; Yin et al., 
2014).  
In this study, we investigated the interplay of ASYN with a group of intracellular 
trafficking genes collectively known as Rab GTPases that are involved in a multitude of 
vesicular trafficking pathways (Stenmark, 2009). In order to achieve this, we utilized 
native, untagged ASYN as well as a C-terminal modified version of ASYN, that forms 
protein inclusions with LB-like characteristics (McLean et al., 2001; Klucken et al., 2012; 
Yin et al., 2014), and a library of EGFP-tagged Rab GTPases, as well as a mutants of 
selected Rab proteins without the ability to hydrolyze GTP or have a higher affinity to 
GDP (Bucci et al., 1992, 2000; Vitelli et al., 1997). We also made use of a mouse model 
overexpressing human ASYN under the control of a Thy1 promoter, resulting in a pre-
PD-like phenotype with motor and cognitive impairment for our in vivo protein analysis 
(Rockenstein et al., 2002; Lam et al., 2011; Chesselet et al., 2012).  
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5.1 A screen in cells accumulating ASYN inclusions reveals mislocalized 
trafficking markers 
While various studies have confirmed the interaction of ASYN with Rab GTPases, we 
present here a comprehensive screen of a majority of members of the Rab GTPase 
family with a variant of ASYN prone to inclusion formation in a mammalian cell line. 
Modifications of the C-terminus of ASYN have been shown to regulate ASYN aggregation 
and protein-protein interaction in the past (Chandra et al., 2005; Garcia-Reitböck et al., 
2010; Levitan et al., 2011; Yin et al., 2014) and this is also the case in this variant of 
ASYN, termed SynT (McLean et al., 2001; Klucken et al., 2012). 
Expressed alone alongside an empty vector, all investigated Rab proteins distribute in 
accordance to their cellular function (Hutagalung and Novick, 2011). Overexpression of 
Rab GTPases sometimes results in overly large target vesicles or clustering, but this has 
not been found to be of negative effect to the cell by itself (Barbieri et al., 1996; Bucci et 
al., 2000; Chan et al., 2011).  
Most Rab proteins were mislocalized, away from their normal cellular compartment, 
upon inclusion formation (compare Table 6). In cells without inclusions, SynT lacked any 
obvious effect on the morphology of Rab proteins. Upon formation of inclusions positive 
for SynT, however, most Rab proteins were localized away from their target membranes 
and was diffusely distributed through the cytoplasm. Also, Rab proteins tended to 
colocalize with the SynT mediated inclusions regardless of their original pathway. This 
hints at pathological ASYN disturbing at least one trafficking pathway, possibly one 
central to all, or most other cellular vesicle trafficking pathways. Intriguingly, this 
tendency of Rab proteins to localize to SynT positive inclusions did not affect Rab7, a 
Rab GTPase localized to late endosomes and lysosomes and an important factor for 
autophagosome formation. On the other hand, other Rab GTPases associated with 
autophagosome formation, Rab5A (Ravikumar et al., 2008; Ao et al., 2014) and Rab33B 
(Itoh et al., 2008), did colocalize with SynT inclusions at least partially. The colocalization 
of Rab GTPases with ASYN mediated aggregates has been reported previously for yeast 
(Soper et al., 2011), but never in this scope in mammalian cells. Further, in this cited 
study, the yeast homologue of Rab7, Ypt7, also colocalized with the aggregates, which is 
the not the case in our investigations.  
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Contrary to this, most Rab GTPases did not have any obvious effect on the formation of 
SynT inclusions. While the initial screen was not quantitative and only targeted obvious 
changes in either Rab proteins or SynT distribution and behavior, it became obvious that 
inclusion formation was increased with the expression of Rab7. Interestingly, this is also 
the Rab protein which did not localize to the SynT mediated inclusions. In the case of 
Rab8A, a decrease in the amount of condensed nuclei indicating cellular toxicity, and an 
effect on ASYN toxicity has been observed in the past (Gitler et al., 2008).  
We eventually selected three major candidates for further investigation, all of which are 
located in the endosomal pathway: Rab5A, Rab7 and Rab8A. 
Rab5A is located at early endosomes and a regulator of clathrin mediated endocytosis 
(Bucci et al., 1992; Zeigerer et al., 2012), as well as endocytic sorting (Deinhardt et al., 
2006; Zeigerer et al., 2012) and has been found to interact with mutant A30P ASYN in 
transgenic mice (Dalfó et al., 2004b). Rab5A positive compartments turn into Rab7 
positive, late endosomal and finally lysosomal vesicles during a process termed Rab 
conversion (Rink et al., 2005; Poteryaev et al., 2010; Zeigerer et al., 2012). Cargo in the 
early endosome does not so much leave the vesicle as the whole vesicle matures into 
the degradation pathway. The discrepancy in our results in regards to Rab5A and Rab7 
in the presence of SynT positive protein inclusions is therefore intriguing, and these two 
candidates were selected for their different behavior despite their localization in 
adjacent pathways. Rab8A is localized at tubular recycling endosomes in the TGN 
secretory pathway (Hattula et al., 2006; Henry and Sheff, 2008) and we were curious 
whether the previously discovered alleviation of toxicity (Gitler et al., 2008) would also 
be replicable in our model. 
 
5.2 Endosomal Rab proteins alter the size and pattern of ASYN 
inclusions  
We observed inclusion formation of ASYN in our cell model in the presence and absence 
of EGFP-fused Rab5A and Rab7. We could establish a strong trend towards an increase 
in inclusion formation with co-expression with Rab5A and a significant increase of 
inclusions when Rab7 was co-expressed. We could also show an increase in inclusion 
formation in the presence of Rab8A which acted protective in light of SynT mediated 
toxicity (Yin et al., 2014). Similar results were recently obtained in a study with Rab11A, 
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another Rab GTPase located at recycling endosomes (Chutna et al., 2014). It is striking 
that we could determine an increase in inclusion formation with Rab7, which does not 
localize with ASYN mediated inclusions, but not an alteration in cellular toxicity. While 
Rab5A, Rab7 and Rab8A all localize to endosomal compartments, the trafficking 
pathways are different and Rab8A is involved in exocytosis while Rab5A and Rab7 are 
located in the sorting and degradation pathway. On the other hand, we could determine 
a strong colocalization with Rab7 and untagged, native ASYN. While ASYN is often 
present as a free, unstructured protein in the cytosol, we could determine discreet 
punctate structures in the cells. Upon investigation in our colocalization experiments 
these were found to be of endosomal nature due to their strong colocalization with 
endosomal Rab5A. While ASYN has been found in in vesicles of unknown origin (Lee et 
al., 2005), and also has been found localized to endosomal structures in HEK293T and 
SH-SY5Y cells (Hasegawa et al., 2011) before, we here present the direct comparison 
between these two pathways. It has been proposed before that ASYN monomers and 
intermediate structures are cleared via the lysosome (Lee et al., 2004; Hasegawa et al., 
2011) and our experiments show that native ASYN can be transported via endosomes to 
the lysosomal pathway. This is also concurrent with our results that both Rab5A and 
Rab7 are able to alter particulate size of native ASYN in a cellular context to different 
degrees. As ASYN oligomers could be shown to be degraded by the lysosome (Sevlever 
et al., 2008; Crabtree et al., 2014), the expression of both Rab GTPases might enhance 
this process. We can see higher molecular weight oligomer fractions with the co-
expression of Rab5A, which might mean an increased sorting activity and clearance by 
the degradation pathway, as we see a comparatively stronger signal with the expression 
of Rab7.  
The opposite results we observed in our model of inclusion formation likely present a 
disturbance of this sorting pathway. A likely scenario for the effect of ASYN inclusions on 
Rab5A might be that Rab5A positive endosomes get caught in the inclusions formed by 
ASYN, while lysosomes do not suffer this fate. This might also explain why Rab5A 
positive compartments are enlarged in ASYN transgenic animals and human cases of DLB 
(Sancenon et al., 2012). It is also possible that by overexpressing the Rab proteins we 
push the system in this direction, i.e. the increased amount of endosomes in the cell due 
to Rab5 overexpression leads to molecular crowding and endosomes stick to the 
inclusions. On the other hand, by overexpressing Rab7 we increase the number of 
lysosomes and might also increase protein turnover. This could also explain the increase 
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in inclusion formation as misfolded proteins are often spatially sequestered into 
compartment like e.g. Q-bodies (Escusa-Toret et al., 2013) in an attempt to improve 
cellular fitness. In axons, the retrograde transport of compartments positive for Rab7 as 
well as autophagosomes was found to be impaired by the formation of Lewy neurites 
(Volpicelli-Daley et al., 2014). However, this study utilized recombinant pre-formed 
fibrils rather than a genetically encoded inclusion model. 
 
5.3 Recycling of ASYN to the plasma membrane is influenced by 
endosomal Rab proteins 
The secretion of ASYN has been a topic of much discussion, and while it is indisputable 
that ASYN can be endocytosed (Sung et al., 2001; Liu et al., 2009), the question of 
exocytosis is not concluded. Prion-like transmission, exosomes, regulated exocytosis and 
tunneling nanotubes have been proposed (Kordower et al., 2008a, 2008b; Steiner et al., 
2011), a hypothesis that might explain Braak staging of the disorder (Braak et al., 2002a, 
2002b, 2004). The expression of a dominant negative version of vacuolar protein 4 led to 
an increase in ASYN release (Hasegawa et al., 2011) and dominant negative mutant of 
Rab11A, which is located at recycling endosomes, had the same effect (Chutna et al., 
2014). Rab11A overexpression also potentially alleviates ASYN mediated toxicity at the 
synapse, restoring the non-pathological phenotype and regulating neurotransmitter 
release (Breda et al., 2014). Taking all of this into account, we wanted to know whether 
one of our candidates would be able to modulate ASYN secretion either in our inclusion 
model or with native ASYN.  
While Rab5A is involved in endocytosis in general and endocytosis of ASYN in particular 
(Sung et al., 2001), data about the effect of Rab5A overexpression on sorting activity is 
yet missing. Interestingly, when ASYN and Rab5A wt or the constitutively active mutant 
Q79L are overexpressed, we can see an increase in ASYN release. This might be 
consistent with an increase in sorting activity into the recycling or exocytic pathway, 
although a previous study could not determine alterations in membrane recycling upon 
expression of constitutive active Rab5A (Ceresa et al., 2001). However, ASYN is not only 
present as a free protein in endosomes, but also occurs in multivesicular bodies (MVBs) 
and is exocytosed in exosomes (Emmanouilidou et al., 2010; Steiner et al., 2011) and 
Rab5 regulates the motility of endosomes alongside microtubuli (Nielsen et al., 1999). 
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On the other hand, knockdown of Rab11A or expression of the dominant negative 
mutant led to an increase of ASYN secretion, hinting at a different pathway of ASYN 
recycling (Chutna et al., 2014). We therefore think that native ASYN is recycled to the 
plasma membrane via a pathway that is at least partially Rab5A dependent. This is 
supported by our observations that upon expression of the dominant negative form of 
Rab5A, secretion is reduced, though not abolished. On the other hand, our observations 
could hint at a mechanism of compensation for excessive potentially harmful protein 
within the cell. In transgenic animals, an increase in size of Rab5A positive 
compartments was observed (Sancenon et al., 2012) and Rab5A is regionally 
upregulated in mild cognitive disorder and AD (Ginsberg et al., 2010, 2011). Further, we 
can see a reduction of secretion of ASYN in our cellular inclusion model with expression 
of the constitutive active mutant while it remains unaffected when the pathway is 
impaired with dominant negative Rab5A N133I. Since in both cases we investigate a 
model that is based on overexpression, it would be interesting to see results from cells 
that natively secrete ASYN while at the same time overexpressing Rab5A Q79L or N133I. 
Overall, it is possible that Rab5A is able to help recycle oligomeric ASYN, but not higher 
molecular weight inclusions or aggregates.  
With Rab7 we observed a decrease for all three variants in both models. In the case of 
Rab7 wt and constitutive active Q67L we can probably explain it with higher protein 
turnover due to an increase in lysosome number and size. Interesting to note is that one 
study found a slight increase in ASYN secretion when Rab7 was co-expressed (Ejlerskov 
et al., 2013), but this was in a cellular model employing the A30P mutant, which is 
known to not possess the same membrane binding capabilities as wt ASYN (Jo et al., 
2004; Wislet-Gendebien et al., 2008). We also have to take into account that while ASYN 
was shown to be secreted into the extracellular space, the ELISA method only measures 
free ASYN. On the other hand, ASYN is also released from the cell in exosomes 
(Emmanouilidou et al., 2010; Danzer et al., 2012), which derive from MVBs and 
surrounded by a membrane (Emmanouilidou et al., 2010). In a previous study with 
Rab11A, alterations of the activity state of this Rab protein associated with recycling 
endosomes did not change secretion of ASYN via exosomes (Chutna et al., 2014). On the 
other hand, MVBs are positive for Rab7 (Bucci et al., 2000) and Rab7 positive structures 
increase with Rab7 overexpression (Bucci et al., 2000). This why in our study with 
overexpression of wt and constitutive active Rab7 might lead to an increase of ASYN 
secretion via this pathway. Further, we know that dominant negative Rab7 leads to a 
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loss of lysosomal acidification (Bucci et al., 2000) and expression of dominant negative 
vacuolar protein 4 lead to an increase in secretion of ASYN (Hasegawa et al., 2011). We 
therefore also expected an increase or no change in ASYN secretion and our findings did 
not support those expectations. For native ASYN as well as for the inclusion model we 
also see a decrease in secretion upon co-expressing Rab7 T22N. One explanation is that 
ASYN is retained in the cell, as one study found that Rab7 T22N inhibits secretion of 
Flightless (Lei et al., 2012), an actin remodeling protein usually secreted via the 
lysosomal pathway. While the authors found increased levels of Flightless in the cells, 
we cannot determine the same for intracellular ASYN in immunoblot analysis, which 
might be due to the metabolic differences between fibroblasts and H4 cells. On the 
other hand, in rat dorsal root ganglion neurons, the expression of dominant negative 
Rab7 had no effect on the secretory pathway (Saxena et al., 2005). As a final 
explanation, ASYN might be degraded via other pathways, like the UPS, when the 
lysosomal pathway is disturbed or AYN might be retained in autophagic vacuoles that 
form with Rab7 T22N expression as previously investigated (Jäger et al., 2004). We can 
exclude, however, that the changes in ASYN secretion are correlated with cell death, 
which points at an active pathway regulated by the endocytic recycling and degradation 
machinery. 
Altogether, we found evidence that Rab5A and Rab7 are involved in the secretory and 
degradation pathway in H4 neuroglioma cells. 
 
5.4 Constitutive ASYN expression in vivo leads to dysregulation of the 
degradation pathway 
Finally, we wanted to investigate our observations in regards to the degradation 
pathway in an in vivo model of ASYN pathology. For this purpose, we used a mouse 
model that overexpresses full length human ASYN under the control of the Thy1 
promoter (Rockenstein et al., 2002; Chesselet et al., 2012). We initially found an 
upregulation of Rab7 in 26 week old mice. This is not concurrent with our findings in 
either of our cell cultures models, where expression of transiently overexpressed Rab7 
was unaffected by the expression of ASYN. However, it is hard to model an age related 
condition in cell culture and even a model like our model of inclusion formation that 
mimics certain aspects of the pathology can only supply a limited amount of 
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information. In order to determine whether the increase in Rab7 was an age-related 
phenomenon, we chose to investigate individuals at two additional ages and also take 
more markers of the lysosomal pathway into account.  
GAPDH is a well-known substrate of the lysosome and can be used as an indicator of 
lysosomal function (Aniento et al., 1993) and we used it to assess protein degradation in 
the investigated brain areas. In young and middle aged mice, soluble GAPDH is elevated 
or remains level with the amounts found in wt littermates, although in aged mice, levels 
decrease in most brain areas. GAPDH possesses two surface cysteines that are known to 
be oxidized to disulfide bonds under conditions of oxidative stress and form insoluble 
aggregates (Nakajima et al., 2007). In our investigations, we only considered the soluble 
fraction and therefore cannot evaluate insoluble GAPDH levels. It is interesting to note, 
that the formation of the disulfide bond also increases oxidative stress and this 
aggregate formation participates in cell death (Nakajima et al., 2009). Further, GAPDH is 
translocated into the nucleus under conditions of oxidative stress (Dastoor and Dreyer, 
2001) and these have been observed in PD and ASYN pathologies (Dexter et al., 1987; 
Fariello, 1988; Spina and Cohen, 1989; Sofic et al., 1992; Sian et al., 1994; Hashimoto et 
al., 1999; Nakaso et al., 2013). Our observations in regards to GAPDH only target the 
cytoplasmatic fraction and we therefore cannot make any claims in regards to the levels 
of GAPDH in the nucleus. However, GAPDH has been identified as a potential 
therapeutic target in neurodegenerative diseases, PD among them (Berry, 2004). We 
suggest that our findings in regards to GAPDH should be further investigated to also take 
the nuclear fraction into account. 
An overexpression of Rab7 is concurrent with an increase in number and size of 
lysosomes (Bucci et al., 2000) and it is striking that the increased expression of Rab7 is 
present at all ages and brain regions we investigated. Regionally increased expression of 
Rab7 has been found in human cases of AD and mild cognitive impairment during the 
investigation of post mortem brains (Ginsberg et al., 2010, 2011) and pathological 
mutation in Charchot-Mary-Tooth Disease Type2B usually leads to a constitutively 
activated phenotype (Spinosa et al., 2008). It is also important to note that expression of 
constitutively active Rab7 rescues receptor degradation impairment in LRRK2 pathology 
(Gómez-Suaga et al., 2014). Given our own observations and this study about another 
PD-associated gene, it seems likely that the degradation pathway is key to teasing apart 
the molecular underpinnings of the disease. We therefore were curious whether the 
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increase in Rab7 expression resulted in a functional change of the lysosome in vivo. 
Therefore we investigated the amount of total as well as cleaved CatD, the protease 
mainly responsible for ASYN degradation (Sevlever et al., 2008; Cullen et al., 2009; 
Crabtree et al., 2014). We found an increase of CatD cleavage in transgenic animals 
compared to their wt littermate controls, which hints at an increase activity of the 
lysosomes. It is interesting to note that inactivation of CatD leads to the formation of 
ASYN positive inclusions and higher molecular weight species (Qiao et al., 2008; Cullen 
et al., 2009; Crabtree et al., 2014). However, CatD ablation is also associated with 
lysosomal storage disease (Koike et al., 2000; Vitner et al., 2010), while increased CatD 
activity has been linked to neurodegenerative conditions (Hetman et al., 1995; Amritraj 
et al., 2013). In association with PD, elevated CatD levels were found in a chronic MPTP 
monkey model distal from the site of insult where they caused apoptotic events 
(Yelamanchili et al., 2011). While the authors conclude that elevation of CatD activity 
might be causative of the pathology, we have to note that the monkeys were 6-8 years 
of age before receiving MPTP, while our mouse model expresses human ASYN from the 
first postnatal week onwards (Chesselet et al., 2012). Also, since we are evaluating a 
mouse model exhibiting genetic ASYN pathology rather than drug-induced 
parkinsonism, we are confident that our findings are not due to an initial increase CatD 
level. It is also interesting to note that elevated CatD levels have been observed cases of 
AD (Cataldo et al., 1995) and positive modulation of lysosomal enzymes has been 
proposed as a mechanism of treating protein accumulation diseases (Bahr et al., 2012), 
as which synucleinopathies are indubitably categorized. As already noted, the ASYN 
transgene is expressed from the first postnatal week onwards and by the age of 13 
weeks, cells might try to compensate for the increased expression of a potentially 
harmful protein in two ways: i) sequestering the protein into inclusions which were 
observed during extensive characterization of the mouse line (Chesselet et al., 2012) and 
ii) by increasing the activity of the degradation machinery that we can show both with 
the elevated expression of Rab7 and the increased cleavage of CatD. Both of these 
observations would also explain our findings in the inclusion model, where 
overexpression of Rab7 resulted in an increase in inclusion formation. Since we also 
could not observe a change in toxicity levels, taken together, these findings indicate that 
the formation of ASYN deposits are the attempt by cells to maintain homeostasis. 
Intriguingly, we see a decrease of cleaved CatD levels in aged mice compared to 
littermate controls. We think these findings might indicate a progressive failure of the 
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degradation machinery and maintenance in proteostasis in aged mice. This hypothesis 
concurrent with the observation that transgenic mice of this line do not show an 
increased mortality until the age of 14 months, after which survival rates drop sharply 
compared to wt littermates (Chesselet et al., 2012).   
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In this study, we showed the ability of ASYN to influence the distribution pattern of Rab 
GTPases upon formation of inclusions with LB-like characteristics. We also showed that 
depending on their intracellular function, Rab GTPases can act as genetic modifiers for 
ASYN inclusion formation and toxicity. With the overexpression of wt ASYN, endosomal 
Rab GTPases can change particulate size and influence the secretion of ASYN, which has 
potential implications on spreading of ASYN pathology between cells. In an in vivo model 
of ASYN pathology we showed the significant modulation of degradation markers at 
different ages, suggesting a compensatory mechanism to remove excess ASYN. Our 
study illustrates ASYN pathology in the endo-lysosomal pathway, which is one of the 
most important and most critical of the cell.  
To expand our findings, further in vivo evaluations in models of ASYN pathology will be 
necessary, including an analysis of insoluble fractions of brain lysates. Rab GTPases are 
molecular switches, therefore downstream targets of Rab5A and Rab7 should be 
screened for dysregulation in our employed models, as this might only present the start 
of a cascade of dysregulation. We also suggest a functional investigation of the Rab 
conversion step from Rab5A to Rab7 via fluorescent endocytic markers destined for the 
degradation pathway. This will shed light on whether lysosomal biogenesis is impaired in 
ASYN pathology.  
PD is an age-related disorder that is classically related to motor symptoms. However, 
recent research has shown that the pathology also spreads into unrelated systems 
causing symptoms that range from loss olfaction to sleep disorders. These non-classical 
symptoms often precede the clinical onset of the disease by decades and hint at an 
underlying biological explanation of PD pathology. Protein trafficking to and from target 
membranes is of great importance in all cell types, but neurons are highly specialized 
and polarized cells. In such strongly compartmentalized structures, disrupting the fine-
tuned homeostasis of protein trafficking has to result in debilitating consequences. In 
this case, the PD-associated vulnerability of dopaminergic neurons located in the 
substantia nigra is specific to their biology and the consequent loss of dopamine in the 
striatum a debilitating side effect of the disease. This is especially true as a disruption in 
vesicle trafficking will affect vesicles carrying dopamine, which is known to produce 
reactive oxygen species. Our finding that the endo-lysosomal system is impaired by 
ASYN pathology, and that modifying trafficking proteins located in this pathway alters 
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ASYN mediated toxicity, provide important insight into the molecular underpinnings of 
PD. Our observations regarding the modulation in secretion of ASYN also highlight an 
important element of PD pathology transmission to neighboring neurons. By 
investigating the protein transport pathways, identifying dysregulated trafficking steps 
and modifiers of ASYN toxicity, we have taken tentative strides towards the 
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